

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, G01N 33/53	A1	(11) International Publication Number: WO 99/06559 (43) International Publication Date: 11 February 1999 (11.02.99)
(21) International Application Number: PCT/US98/15598 (22) International Filing Date: 28 July 1998 (28.07.98) (30) Priority Data: 60/054,461 1 August 1997 (01.08.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/054,461 (CON) Filed on 1 August 1997 (01.08.97) (71) Applicant (for all designated States except US): THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Se-Jin [US/US]; 6711 Chokeberry Road, Baltimore, MD 21209 (US). McPHERRON, Alexandra [US/US]; 519 W. Pratt Street #218, Baltimore, MD 21201 (US). (74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHODS TO IDENTIFY GROWTH DIFFERENTIATION FACTOR (GDF) RECEPTORS (57) Abstract <p>The present invention provides receptors for the growth differentiation factor (GDF) family of growth factors and methods of identifying such receptors. Also included are methods of identifying antibodies which bind to the receptors, peptide fragments of the receptor which inhibit GDF binding, GDF receptor-binding agents capable of blocking GDF binding to the receptor. The receptors of the invention allow the identification of antagonists or agonists useful for agricultural and human therapeutic purposes.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

METHODS TO IDENTIFY GROWTH DIFFERENTIATION FACTOR (GDF) RECEPTORS

1. *Field of the Invention*

This invention relates generally to ligand-receptor interactions and more specifically to growth differentiation factor receptor proteins and the ligands that bind to such receptors and methods of use therefor.

2. *Description of Related Art*

The transforming growth factor β (TGF- β) superfamily encompasses a group of structurally-related proteins which affect a wide range of differentiation processes during embryonic development. The family includes, Mullerian inhibiting substance (MIS), which is required for normal male sex development (Behringer, *et al.*, *Nature*, 345:167, 1990), *Drosophila* decapentaplegic (DPP) gene product, which is required for dorsal-ventral axis formation and morphogenesis of the imaginal disks (Padgett, *et al.*, *Nature*, 325:81-84, 1987), the *Xenopus* Vg-1 gene product, which localizes to the vegetal pole of eggs ((Weeks, *et al.*, *Cell*, 51:861-867, 1987), the activins (Mason, *et al.*, *Biochem. Biophys. Res. Commun.*, 135:957-964, 1986), which can induce the formation of mesoderm and anterior structures in *Xenopus* embryos (Thomsen, *et al.*, *Cell*, 63:485, 1990), and the bone morphogenetic proteins (BMPs, osteogenin, OP-1) which can induce de novo cartilage and bone formation (Sampath, *et al.*, *J. Biol. Chem.*, 265:13198, 1990). The TGF- β s can influence a variety of differentiation processes, including adipogenesis, myogenesis, chondrogenesis, hematopoiesis, and epithelial cell differentiation (for review, see Massague, *Cell* 49:437, 1987).

The proteins of the TGF- β family are initially synthesized as a large precursor protein which subsequently undergoes proteolytic cleavage at a cluster of basic residues approximately 110-140 amino acids from the C-terminus. The C-terminal regions, or mature regions, of the proteins are all structurally related and the different family

THIS PAGE BLANK (USPTO)

- 2 -

members can be classified into distinct subgroups based on the extent of their homology. Although the homologies within particular subgroups range from 70% to 90% amino acid sequence identity, the homologies between subgroups are significantly lower, generally ranging from only 20% to 50%. In each case, the active species appears to be a disulfide-linked dimer of C-terminal fragments. Studies have shown that when the pro-region of a member of the TGF- β family is coexpressed with a mature region of another member of the TGF- β family, intracellular dimerization and secretion of biologically active homodimers occur (Gray, A. *et al.*, *Science*, 247:1328, 1990). Additional studies by Hammonds, *et al.*, (*Molec. Endocrin.* 5:149, 1991) showed that the use of the BMP-2 pro-region combined with the BMP-4 mature region led to dramatically improved expression of mature BMP-4. For most of the family members that have been studied, the homodimeric species has been found to be biologically active, but for other family members, like the inhibins (Ling, *et al.*, *Nature*, 321 :779, 1986) and the TGF- β s (Cheifetz, *et al.*, *Cell*, 48:409, 1987), heterodimers have also been detected, and these appear to have different biological properties than the respective homodimers.

The study of receptor-ligand interactions has revealed a great deal of information about how cells respond to external stimuli. This knowledge has led to the development of therapeutically important compounds, such as erythropoietin, colony stimulating factors and PDGF.

20

Summary of the Invention

The present invention provides receptors for the growth differentiation factor (GDF) growth factor family. These receptors are useful for identifying antagonists and agonists for agricultural and human therapeutic purposes.

25 In a first embodiment, the invention provides a recombinant cell line that expresses growth differentiation factor-8 (GDF-8) or growth differentiation factor-11 (GDF-11) receptor polypeptide. Also included are antibodies that bind to GDF receptors, polynucleotides encoding the receptors and the GDF receptor proteins themselves.

- 3 -

Peptide fragments of GDF receptors, such as the GDF-8 or GDF-11 receptors, are also included. Such peptides may be useful in inhibiting binding of GDF-8 or GDF-11 to either its own receptor or another GDF-receptor (e.g., GDF-8 and -11 may bind the same receptor).

- 5 In another embodiment, the invention provides a substantially purified GDF-8-binding agent, wherein the binding agent inhibits GDF-8 binding to GDF-8 receptor. Such agents that inhibit GDF-11 binding are also included.

In yet another embodiment, the invention provides a method for identifying a GDF receptor polypeptide including incubating components such as GDF polypeptide and a
10 cell expressing a receptor or a soluble receptor under conditions sufficient to allow the GDF to bind to the receptor; measuring the binding of the GDF polypeptide to the receptor; and isolating the receptor.

The invention also includes a method for identifying a compound that binds to GDF receptor polypeptide including incubating components comprising the compound and
15 GDFpolypeptide under conditions sufficient to allow the components to interact and measuring the binding or effect of binding of the compound to GDF receptor polypeptide.

The invention also provides non-human transgenic animals that have a phenotype characterized by expression of GDF-receptor polypeptide, the phenotype being
20 conferred by a transgene contained in the somatic and germ cells of the animal, the transgene comprising a nucleic acid sequence which encodes GDF- receptor polypeptide. Methods of producing such transgenic animals are also included.

In another embodiment, the invention includes a method for inhibiting the expression of GDF-receptor in a cell including contacting GDF-receptor with an inhibiting effective
25 amount of an antisense oligonucleotide that binds to a segment of an mRNA transcribed

- 4 -

from a GDF-receptor gene, whereby the binding of the antisense to the mRNA segment inhibits GDF-receptor expression.

Brief Description of the Figures

Figure 1a and 1b are the nucleotide and amino acid sequence of murine GDF-8.

- 5 Figure 1c and 1d are the nucleotide and amino acid sequence of human GDF-8.

Figures 2a-2e are the nucleotide and amino acid sequence of baboon, bovine, chicken, rat, and turkey GDF-8.

Figures 3a and 3b are Northern blots showing expression of GDF-8 in muscle and in various species, respectively.

- 10 Figures 4a and 4b show the nucleotide and amino acid sequence of murine GDF-11 and expression of GDF-11, respectively.

Figure 5 shows an autoradiogram showing GDF-8.

Figures 6 and 7 show binding studies for GDF-8.

Figures 8-11 show 4 myoblast cell lines that do not bind GDF-8.

- 15 Figure 12 shows the construction of GDF-11 null mice by homologous targeting. .a) is a map of the GDF-11 locus (top line) and targeting construct (second line). The black and stippled boxes represent coding sequences for the pro-and C-terminal regions, respectively. The targeting construct contains a total of 11 kb of homology with the GDF-11 gene. A probe derived from the region upstream of the 3' homology fragment
20 and downstream of the first EcoRI site shown hybridizes to a 6.5 kb EcoRI fragment in the GDF-11 gene and a 4.8 kb fragment in a homologously targeted gene. Abbreviations: X, XbaI; E, EcoRI. b) Geneomic Southern of DNA prepared from F1 heterozygous mutant mice (lanes 1 and 2) and offspring derived from a mating of these mice (lanes 3-12).

- 25 Figure 13 shows kidney abnormalities in GDF-11 knockout mice. Kidneys of newborn animals were examined and classified according to the number of normal sized or small kidneys as shown at the top. Numbers in the table indicate number of animals falling into each classification according to genotype.

- 5 -

Figure 14 shows homeotic transformations in GDF-11 mutant mice. a) Newborn pups with missing (first and second from left) and normal looking tails. b-j) Skeleton preparations for newborn wild-type (b, e, h), heterozygous (c, f, I) and homozygous (d, g, j) mutant mice. Whole skeleton preparations (b-d), vertebral columns (e-g),
5 vertebrosteral ribs (h-j) showing transformations and defects in homozygous and heterozygous mutant mice. Numbers indicate thoracic segments.
Figure 15 is a table summarizing anterior transformations in wild-type, heterozygous and homozygous GDF-11 mice.

Detailed Description of the Invention

- 10 The invention provides an isolated polynucleotide sequence encoding the receptors of the invention. The term "isolated" as used herein includes polynucleotides substantially free of other nucleic acids, proteins, lipids, carbohydrates or other materials with which it is naturally associated. Polynucleotide sequences of the invention include DNA, cDNA and RNA sequences which encode GDF receptors. It is understood that all
15 polynucleotides encoding all or a portion of GDF receptors are also included herein, as long as they encode a polypeptide with GDF receptors activity (*e.g.*, bind to GDF). Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, portions of the mRNA sequence may be altered due to alternate RNA splicing patterns or the use of alternate promoters for RNA transcription.
- 20 As another example, GDF receptor polynucleotide may be subjected to site-directed mutagenesis. The polynucleotide sequence for GDF receptors also includes antisense sequences. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are
25 included in the invention as long as the amino acid sequence of GDF receptors polypeptide encoded by the nucleotide sequence is functionally unchanged. Also included are nucleotide sequences which encode GDF receptors polypeptide.

- 6 -

The polynucleotide encoding GDF receptors for GDFs such as GDF-8 or 11 (shown in the figures). When the sequence is RNA, the deoxyribonucleotides A, G, C, and T are replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are fragments (portions) of the above-described nucleic acid sequences that are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes the GDF receptor. "Selective hybridization" as used herein refers to hybridization under moderately stringent or highly stringent physiological conditions (See, for example, the techniques described in Maniatis et al., 1989 Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., incorporated herein by reference), which distinguishes related from unrelated nucleotide sequences.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, *e.g.*, high stringency conditions, or each of the conditions can be used, *e.g.*, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

- 7 -

Specifically disclosed herein is a cDNA sequence for GDF receptors. SEQ ID NO:3 represents the wild-type sequence and SEQ ID NO:1 represents a cDNA which encodes GDF receptors having a conservative substitution of Leucine for Alanine at amino acid residue 127. The result of this conservative variation should not affect biological activity of GDF receptors polypeptide or peptides containing the variation (see Example 5).

DNA sequences of the invention can be obtained by several methods. For example, the DNA can be isolated using hybridization or computer-based techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences; 2) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features; 3) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of interest; 4) computer searches of sequence databases for similar sequences; and 5) differential screening of a subtracted DNA library.

Preferably the GDF receptor polynucleotide of the invention is derived from avian, bovine, ovine, piscine, murine, human or porcine. Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. Oligonucleotide probes, which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent

- 8 -

hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, *et al.*, *Nucl. Acid Res.*, 9:879, 1981). Alternatively, a subtractive
5 library, as illustrated herein is useful for elimination of non-specific cDNA clones.

When the entire sequence of amino acid residues of the desired polypeptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the synthesis of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries
10 which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the polypeptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences
15 duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, *et al.*, *Nucl. Acid Res.*, 11:2325, 1983).

A cDNA expression library, such as lambda gt11, can be screened indirectly for GDF
20 receptors peptides having at least one epitope, using antibodies specific for GDF receptors. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of GDF receptors cDNA.

Alterations in GDF receptors nucleic acid include intragenic mutations (*e.g.*, point mutation, nonsense (stop), missense, splice site and frameshift) and heterozygous or
25 homozygous deletions. Detection of such alterations can be done by standard methods known to those of skill in the art including sequence analysis, Southern blot analysis, PCR based analyses (*e.g.*, multiplex PCR, sequence tagged sites (STSs)) and *in situ*

- 9 -

hybridization. Such proteins can be analyzed by standard SDS-PAGE and/or immuno-precipitation analysis and/or Western blot analysis, for example.

- DNA sequences encoding GDF receptors can be expressed *in vitro* by DNA transfer into a suitable host cell. "Host cells" are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.
- 10 In the present invention, the GDF receptor polynucleotide sequences may be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the GDF receptors genetic sequences. Such expression vectors contain a promoter sequence which facilitates the efficient transcription of the inserted
- 15 genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, *Gene* 56:125, 1987), the pMSXND expression vector for expression in mammalian cells
- 20 (Lee and Nathans, *J. Biol. Chem.*, 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (*e.g.*, T7, metallothionein I, or polyhedrin promoters).

- Polynucleotide sequences encoding GDF receptors can be expressed in either
- 25 prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA

- 10 -

vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing the GDF receptors coding sequence and appropriate transcriptional/translational control signals. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* recombination/genetic techniques. (See, for example, the techniques described in Maniatis et al., 1989 Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.)

A variety of host-expression vector systems may be utilized to express the GDF receptors coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the GDF receptors coding sequence; yeast transformed with recombinant yeast expression vectors containing the GDF receptors coding sequence; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing the GDF receptors coding sequence; insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing the GDF receptors coding sequence; or animal cell systems infected with recombinant virus expression vectors (*e.g.*, retroviruses, adenovirus, vaccinia virus) containing the GDF receptors coding sequence, or transformed animal cell systems engineered for stable expression. Since GDF receptors has not been confirmed to contain carbohydrates, both bacterial expression systems as well as those that provide for translational and post-translational modifications may be used; *e.g.*, mammalian, insect, yeast or plant expression systems.

Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see *e.g.*, Bitter et al., 1987, Methods in Enzymology 153:516-544). For example, when

- 11 -

cloning in bacterial systems, inducible promoters such as pL of bacteriophage γ , plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the inserted GDF receptors coding sequence.

In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et al., 1987, Expression and Secretion Vectors for Yeast, *in* Methods in Enzymology, Eds. Wu & Grossman, 31987, Acad. Press, N.Y., Vol. 153, pp.516-544; Glover, 1986, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular Biology of the Yeast *Saccharomyces*, 1982, Eds. Strathern et al., Cold Spring Harbor Press, Vols. I and II. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used (Cloning in Yeast, Ch. 3, R. Rothstein In: DNA Cloning Vol.11, A Practical Approach, Ed. DM Glover, 1986, IRL Press, Wash., D.C.). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

Eukaryotic systems, and preferably mammalian expression systems, allow for proper post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, phosphorylation, and advantageously, plasma membrane insertion of the gene product may be used as host cells for the expression of GDF receptors.

- 12 -

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, the GDF receptors coding sequence may be ligated to an adenovirus transcription/-translation control complex, *e.g.*, the late promoter and tripartite leader sequence.

5 Alternatively, the vaccinia virus 7.5K promoter may be used. (*e.g.*, see, Mackett et al., 1982, *Proc. Natl. Acad. Sci. USA* 79: 7415-7419; Mackett et al., 1984, *J. Virol.* 49: 857-864; Panicali et al., 1982, *Proc. Natl. Acad. Sci. USA* 79: 4927-4931). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver, et al., 1981, *Mol. Cell. Biol.* 1: 486). Shortly

10 after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as, for example, the neo gene. Alternatively, the retroviral genome can be modified

15 for use as a vector capable of introducing and directing the expression of the GDF receptors gene in host cells (Cone & Mulligan, 1984, *Proc. Natl. Acad. Sci. USA* 81:6349-6353). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine IIA promoter and heat shock promoters.

For long-term, high-yield production of recombinant proteins, stable expression is

20 preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the GDF receptors cDNA controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. The selectable marker in the recombinant plasmid confers resistance to the selection and

25 allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine

- 13 -

kinase (Wigler, *et al.*, 1977, *Cell* 11: 223), hypoxanthine-guanine phospho-
ribosyltransferase (Szybalska & Szybalski, 1962, *Proc. Natl. Acad. Sci. USA* 48: 2026),
and adenine phosphoribosyltransferase (Lowy, *et al.*, 1980, *Cell* 22: 817) genes can be
employed in tk-, hgp^rt- or ap^rt- cells respectively. Also, antimetabolite resistance can be
5 used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler,
et al., 1980, *Natl. Acad. Sci. USA* 77: 3567; O'Hare, *et al.*, 1981, *Proc. Natl. Acad. Sci.*
USA 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg,
1981, *Proc. Natl. Acad. Sci. USA* 78: 2072; neo, which confers resistance to the
aminoglycoside G-418 (Colberre-Garapin, *et al.*, 1981, *J. Mol. Biol.* 150: 1); and hygro,
10 which confers resistance to hygromycin (Santerre, *et al.*, 1984, *Gene* 30: 147) genes.
Recently, additional selectable genes have been described, namely trpB, which allows
cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol
in place of histidine (Hartman & Mulligan, 1988, *Proc. Natl. Acad. Sci. USA* 85: 8047);
and ODC (ornithine decarboxylase) which confers resistance to the ornithine
15 decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L.,
1987, In: *Current Communications in Molecular Biology*, Cold Spring Harbor
Laboratory ed.).

When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate
co-precipitates, conventional mechanical procedures such as microinjection, electro-
20 poration, insertion of a plasmid encased in liposomes, or virus vectors may be used.
Eukaryotic cells can also be cotransformed with DNA sequences encoding the GDF
receptors of the invention, and a second foreign DNA molecule encoding a selectable
phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use
a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to
25 transiently infect or transform eukaryotic cells and express the protein. (see for example,
Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

- 14 -

Cell Lines

- In one embodiment, the present invention relates to stable recombinant cell lines, the cells of which express GDF receptor polypeptides and contain DNA that encodes GDF receptors. Suitable cell types include but are not limited to cells of the following types:
- 5 NIH 3T3 (Murine), C2C12, L6, and P19. C2C12 and L6 myoblasts will differentiate spontaneously in culture and form myotubes depending on the particular growth conditions (Yaffe and Saxel, 1977; Yaffe, 1968). P19 is an embryonal carcinoma cell line. Such cells are described, for example, in the Cell Line Catalog of the American Type Culture Collection (ATCC). These cells can be stably transformed by a method
 - 10 known to the skilled artisan. See, for example, Ausubel *et al.*, *Introduction of DNA Into Mammalian Cells*, in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, sections 9.5.1-9.5.6 (John Wiley & Sons, Inc. 1995). "Stable" transformation in the context of the invention means that the cells are immortal to the extent of having gone through at least 50 divisions.
 - 15 GDF receptors can be expressed using inducible or constitutive regulatory elements for such expression. Commonly used constitutive or inducible promoters, for example, are known in the art. The desired protein encoding sequence and an operably linked promoter may be introduced into a recipient cell either as a non-replicating DNA (or RNA) molecule, which may either be a linear molecule or, more preferably, a closed
 - 20 covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the desired molecule may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced sequence into the host chromosome. Therefore the cells can be transformed stably or transiently.
 - 25 An example of a vector that may be employed is one which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector.

- 15 -

The marker may complement an auxotrophy in the host (such as leu2, or ura3, which are common yeast auxotrophic markers), biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by
5 co-transfection.

In a preferred embodiment, the introduced sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that
10 contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

For a mammalian host, several possible vector systems are available for expression. One
15 class of vectors utilize DNA elements which provide autonomously replicating extra-chromosomal plasmids, derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, or SV40 virus. A second class of vectors include vaccinia virus expression vectors. A third class of vectors relies upon the integration of the desired gene sequences into the host chromosome. Cells which have stably integrated
20 the introduced DNA into their chromosomes may be selected by also introducing one or more markers (e.g., an exogenous gene) which allow selection of host cells which contain the expression vector. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper or the like. The selectable marker gene can either be directly linked to the DNA sequences to be
25 expressed, or introduced into the same cell by co-transformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. The

- 16 -

cDNA expression vectors incorporating such elements include those described by Okayama, H., Mol. Cell. Biol., 3:280 (1983), and others.

Once the vector or DNA sequence containing the construct has been prepared for expression, the DNA construct may be introduced (transformed) into an appropriate host.

- 5 Various techniques may be employed, such as protoplast fusion, calcium phosphate precipitation, electroporation or other conventional techniques.

TRANSGENIC ANIMALS

- In another embodiment, the present invention relates to transgenic animals having cells that express GDF receptors. Such transgenic animals, for example those containing the
- 10 GDF-8 receptor, may have decreased fat content and increased muscle mass. The subject invention provides non-human transgenic animals which are useful as a source of food products with high muscle and protein content, and reduced fat and cholesterol content. The animals have been altered chromosomally in their germ cells and somatic cells so that the production of GDF-8 may be at "normal" levels, however, the GDF-8 receptor
- 15 is produced in reduced amounts, or is completely disrupted, resulting in animals with decreased binding of GDF-8 and higher than normal levels of muscle tissue, preferably without increased fat and/or cholesterol levels. Accordingly, the present invention also includes food products provided by the animals. Such food products have increased nutritional value because of the increase in muscle tissue. The transgenic non-human
- 20 animals of the invention include bovine, porcine, ovine and avian animals, for example.

- The subject invention also provides a method of producing animal food products having increased muscle content. The method includes modifying the genetic makeup of the germ cells of a pronuclear embryo of the animal, implanting the embryo into the oviduct of a pseudopregnant female thereby allowing the embryo to mature to full term progeny,
- 25 testing the progeny for presence of the transgene to identify transgene-positive progeny, cross-breeding transgene-positive progeny to obtain further transgene-positive progeny and processing the progeny to obtain foodstuff. The modification of the germ cell

- 17 -

comprises altering the genetic composition so as to disrupt or reduce the expression of the naturally occurring gene encoding for production of GDF-8 receptor protein. In a particular embodiment, the transgene comprises antisense polynucleotide sequences to the GDF-8 receptor protein. Alternatively, the transgene may comprise a non-functional
5 sequence which replaces or intervenes in the native GDF-8 receptor gene or the transgene may encode a GDF-8 receptor antagonist.

The subject invention also provides a method of producing avian food products having improved muscle content. The method includes modifying the genetic makeup of the germ cells of a pronuclear embryo of the avian animal, implanting the embryo into the
10 oviduct of a pseudopregnant female into an embryo of a chicken, culturing the embryo under conditions whereby progeny are hatched, testing the progeny for presence of the genetic alteration to identify transgene-positive progeny, cross-breeding transgene-positive progeny and processing the progeny to obtain foodstuff.

The term "animal" here denotes all mammalian species except human. It also includes
15 an individual animal in all stages of development, including embryonic and fetal stages. Farm animals (pigs, goats, sheep, cows, horses, rabbits and the like), rodents (such as mice), and domestic pets (for example, cats and dogs) are included within the scope of the present invention.

A "transgenic" animal is any animal containing cells that bear genetic information
20 received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as by microinjection or infection with recombinant virus. "Transgenic" in the present context does not encompass classical crossbreeding or *in vitro* fertilization, but rather denotes animals in which one or more cells receive a recombinant DNA molecule. Although it is highly preferred that this molecule be integrated within the animal's
25 chromosomes, the present invention also contemplates the use of extrachromosomally replicating DNA sequences, such as might be engineered into yeast artificial chromosomes.

- 18 -

The term "transgenic animal" also includes a "germ cell line" transgenic animal. A germ cell line transgenic animal is a transgenic animal in which the genetic information has been taken up and incorporated into a germ line cell, therefore conferring the ability to transfer the information to offspring. If such offspring in fact possess some or all of that information, then they, too, are transgenic animals.

The cDNA that encodes GDF receptors can be fused in proper reading frame under the transcriptional and translational control of a vector to produce a genetic construct that is then amplified, for example, by preparation in a bacterial vector, according to conventional methods. See, for example, the standard work: Sambrook *et al.*,
10 MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Press 1989), the contents of which are incorporated by reference. The amplified construct is thereafter excised from the vector and purified for use in producing transgenic animals.

The term "transgenic" as used herein additionally includes any organism whose genome has been altered by *in vitro* manipulation of the early embryo or fertilized egg or by any transgenic technology to induce a specific gene knockout. The term "gene knockout" as
15 used herein, refers to the targeted disruption of a gene *in vivo* with complete loss of function that has been achieved by any transgenic technology familiar to those in the art. In one embodiment, transgenic animals having gene knockouts are those in which the target gene has been rendered nonfunctional by an insertion targeted to the gene to be
20 rendered non-functional by homologous recombination. As used herein, the term "transgenic" includes any transgenic technology familiar to those in the art which can produce an organism carrying an introduced transgene or one in which an endogenous gene has been rendered non-functional or "knocked out."

The transgene to be used in the practice of the subject invention may be a DNA sequence
25 comprising a modified GDF receptors coding sequence. In a preferred embodiment, the GDF receptor gene is disrupted by homologous targeting in embryonic stem cells. For example, the entire mature C-terminal region of the GDF receptors gene may be deleted

- 19 -

as described in the examples below. Optionally, the GDF receptors disruption or deletion may be accompanied by insertion of or replacement with other DNA sequences, such as a non-functional GDF receptors sequence. In other embodiments, the transgene comprises DNA antisense to the coding sequence for GDF receptors. In another
5 embodiment, the transgene comprises DNA encoding an antibody or receptor peptide sequence which is able to bind to GDF receptors. Where appropriate, DNA sequences that encode proteins having GDF receptors activity but differ in nucleic acid sequence due to the degeneracy of the genetic code may also be used herein, as may truncated forms, allelic variants and interspecies homologues.

10 ***ANTIBODIES WHICH BIND TO GDF RECEPTORS***

In another embodiment, the present invention relates to antibodies that bind GDF receptors that block GDF binding to the receptor. For example, such antibodies may be useful for ameliorating disorders associated with muscle tissue.

A monoclonal antibody which binds to GDF-8 receptor may have the effect of increasing
15 the development of skeletal muscles. In preferred embodiments of the claimed methods, the GDF-8 receptor monoclonal antibody, polypeptide, or polynucleotide is administered to a patient suffering from a disorder selected from the group consisting of muscle wasting disease, neuromuscular disorder, muscle atrophy or aging. The GDF-8 receptor antibody may also be administered to a patient suffering from a disorder selected from
20 the group consisting of muscular dystrophy, spinal cord injury, traumatic injury, congestive obstructive pulmonary disease (COPD), AIDS or cachexia. In a preferred embodiment, the GDF-8 antibody is administered to a patient with muscle wasting disease or disorder by intravenous, intramuscular or subcutaneous injection; preferably, a monoclonal antibody is administered within a dose range between about 0.1 mg/kg to
25 about 100 mg/kg; more preferably between about 1 ug/kg to 75 mg/kg; most preferably from about 10 mg/kg to 50 mg/kg. The antibody may be administered, for example, by bolus injection or by slow infusion. Slow infusion over a period of 30 minutes to 2

- 20 -

hours is preferred. The GDF-8 antibody may be formulated in a formulation suitable for administration to a patient. Such formulations are known in the art.

The dosage regimen will be determined by the attending physician considering various factors which modify the action of the GDF-8 receptor protein, *e.g.* amount of tissue
5 desired to be formed, the site of tissue damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and the types of agent, such as anti-GDF-8 receptor antibodies, to be used in the composition. Generally, systemic or
10 injectable administration, such as intravenous (IV), intramuscular (IM) or subcutaneous (Sub-Q) injection. Administration will generally be initiated at a dose which is minimally effective, and the dose will be increased over a preselected time course until a positive effect is observed. Subsequently, incremental increases in dosage will be made limiting such incremental increases to such levels that produce a corresponding increase
15 in effect, while taking into account any adverse affects that may appear. The addition of other known growth factors, such as IGF I (insulin like growth factor I), human, bovine, or chicken growth hormone which may aid in increasing muscle mass, to the final composition, may also affect the dosage. In the embodiment where an anti-GDF-8 receptor antibody is administered, the anti-GDF-8 antibody is generally administered
20 within a dose range of about 0.1 ug/kg to about 100 mg/kg.; more preferably between about 10 mg/kg to 50 mg/kg.

The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green *et al.*, *Production of Polyclonal Antisera*, in IMMUNOCHEMICAL PROTOCOLS (Manson, ed.), pages 1-5 (Humana Press 1992); Coligan *et al.*, *Production*
25 *of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters*, in CURRENT PROTOCOLS IN IMMUNOLOGY, section 2.4.1 (1992), which are hereby incorporated by reference.

- 21 -

The preparation of monoclonal antibodies likewise is conventional. See, for example, Kohler & Milstein, *Nature* 256:495 (1975); Coligan *et al.*, sections 2.5.1-2.6.7; and Harlow *et al.*, ANTIBODIES: A LABORATORY MANUAL, page 726 (Cold Spring Harbor Pub. 1988), which are hereby incorporated by reference. Briefly, monoclonal

5 antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

10 Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, *e.g.*, Coligan *et al.*, sections 2.7.1-2.7.12 and sections 2.9.1-2.9.3; Barnes *et al.*, *Purification of Immunoglobulin G (IgG)*, in METHODS IN

15 MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (Humana Press 1992). Methods of *in vitro* and *in vivo* multiplication of monoclonal antibodies is well-known to those skilled in the art. Multiplication *in vitro* may be carried out in suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium, optionally replenished by a mammalian serum such as fetal calf serum or trace elements and

20 growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages. Production *in vitro* provides relatively pure antibody preparations and allows scale-up to yield large amounts of the desired antibodies. Large scale hybridoma cultivation can be carried out by homogenous suspension culture in an airlift reactor, in a continuous stirrer reactor, or in immobilized or entrapped cell culture.

25 Multiplication *in vivo* may be carried out by injecting cell clones into mammals histocompatible with the parent cells, *e.g.*, osyngeneic mice, to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. After one to three weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.

- 22 -

Therapeutic applications for antibodies disclosed herein are also part of the present invention. For example, antibodies of the present invention may also be derived from subhuman primate antibody. General techniques for raising therapeutically useful antibodies in baboons can be found, for example, in Goldenberg *et al.*, International Patent Publication WO 91/11465 (1991) and Losman *et al.*, *Int. J. Cancer* 46:310 (1990), which are hereby incorporated by reference.

Alternatively, a therapeutically useful anti-GDF receptors antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi *et al.*, *Proc. Nat'l Acad. Sci. USA* 86:3833 (1989), which is hereby incorporated in its entirety by reference. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones *et al.*, *Nature* 321: 522 (1986); Riechmann *et al.*, *Nature* 332: 323 (1988); Verhoeven *et al.*, *Science* 239: 1534 (1988); Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89: 4285 (1992); Sandhu, *Crit. Rev. Biotech.* 12: 437 (1992); and Singer *et al.*, *J. Immunol.* 150: 2844 (1993), which are hereby incorporated by reference.

Antibodies of the invention also may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas *et al.*, *METHODS: A COMPANION TO METHODS IN ENZYMOLOGY*, VOL. 2, page 119 (1991); Winter *et al.*, *Ann. Rev. Immunol.* 12: 433 (1994), which are hereby incorporated by reference. Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).

- 23 -

In addition, antibodies of the present invention may be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain loci are introduced into
5 strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green *et al.*, *Nature Genet.* 7:13 (1994); Lonberg *et al.*,
10 *Nature* 368:856 (1994); and Taylor *et al.*, *Int. Immunol.* 6:579 (1994), which are hereby incorporated by reference.

Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by
15 conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')₂. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin
20 produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patents No. 4,036,945 and No. 4,331,647, and references contained therein. These patents are hereby incorporated in their entireties by reference. See also Nisonhoff *et al.*, *Arch. Biochem. Biophys.* 89:230 (1960); Porter, *Biochem. J.* 73:119 (1959); Edelman *et al.*, METHODS IN
25 ENZYMOLOGY, VOL. 1, page 422 (Academic Press 1967); and Coligan *et al.* at sections 2.8.1-2.8.10 and 2.10.1-2.10.4.

Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other

- 24 -

enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

For example, Fv fragments comprise an association of V_H and V_L chains. This association may be noncovalent, as described in Inbar *et al.*, *Proc. Nat'l Acad. Sci. USA* 5 69:2659 (1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. See, e.g., Sandhu, *supra*. Preferably, the Fv fragments comprise V_H and V_L chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains connected 10 by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow *et al.*, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 97 (1991); Bird 15 *et al.*, *Science* 242:423-426 (1988); Ladner *et al.*, U.S. patent No. 4,946,778; Pack *et al.*, *Bio/Technology* 11: 1271-77 (1993); and Sandhu, *supra*.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of 20 interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick *et al.*, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 106 (1991).

IDENTIFICATION OF GDF RECEPTORS

25 In another embodiment, the invention provides a method for identifying a GDF receptor polypeptide comprising incubating components comprising GDF polypeptide and a cell expressing a receptor or a soluble receptor under conditions sufficient to allow the GDF

- 25 -

to bind to the receptor; measuring the binding of the GDF polypeptide to the receptor; and isolating the receptor. The GDF may be any of the known GDFs (e.g., GDF-1-16), and preferably is GDF-8 or GDF-11. Methods of isolating the receptors are described in more detail in the Examples section below.

5 *VARIANTS OF GDF RECEPTORS*

The term "GDF receptors variant" as used herein means a molecule that simulates at least part of the structure of GDF receptors. GDF receptor variants may also be useful in preventing GDF binding, thereby ameliorating symptoms of disorders described above.

10 In one embodiment, the present invention relates to peptides and peptide derivatives that have fewer amino acid residues than GDF receptors. Such peptides and peptide derivatives could represent research and diagnostic tools in the study of muscle wasting diseases and the development of more effective therapeutics.

The invention relates not only to peptides and peptide derivatives of naturally-occurring GDF receptors, but also to GDF receptor mutants and chemically synthesized derivatives
15 of GDF receptors that bind GDFs. For example, changes in the amino acid sequence of GDF receptors are contemplated in the present invention. GDF receptors can be altered by changing the DNA encoding the protein. Preferably, only conservative amino acid alterations are undertaken, using amino acids that have the same or similar properties. Illustrative amino acid substitutions include the changes of: alanine to serine; arginine
20 to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine;
25 tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; valine to isoleucine or leucine.

- 26 -

Variants useful for the present invention comprise analogs, homologs, muteins and mimetics of GDF receptors that retain the ability to bind to their respective GDFs. Peptides of the GDF receptors refer to portions of the amino acid sequence of GDF receptors that also retain this ability. The variants can be generated directly from GDF
5 receptors itself by chemical modification, by proteolytic enzyme digestion, or by combinations thereof. Additionally, genetic engineering techniques, as well as methods of synthesizing polypeptides directly from amino acid residues, can be employed.

Peptides of the invention can be synthesized by such commonly used methods as t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise syntheses
10 whereby a single amino acid is added at each step starting from the C terminus of the peptide (See, Coligan, *et al.*, *Current Protocols in Immunology*, Wiley Interscience, 1991, Unit 9). Peptides of the invention can also be synthesized by the well known solid phase peptide synthesis methods described Merrifield, *J. Am. Chem. Soc.*, 85:2149, 1962), and Stewart and Young, *Solid Phase Peptides Synthesis*, (Freeman, San Francisco,
15 1969, pp.27-62), using a copoly(styrene-divinylbenzene) containing 0.1-1.0 mMol amines/g polymer. On completion of chemical synthesis, the peptides can be deprotected and cleaved from the polymer by treatment with liquid HF-10% anisole for about 1/4-1 hours at 0°C. After evaporation of the reagents, the peptides are extracted from the polymer with 1% acetic acid solution which is then lyophilized to yield the crude
20 material. This can normally be purified by such techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent. Lyophilization of appropriate fractions of the column will yield the homogeneous peptide or peptide derivatives, which can then be characterized by such standard techniques as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption
25 spectroscopy, molar rotation, solubility, and quantitated by the solid phase Edman degradation.

Alternatively, peptides can be produced by recombinant methods as described below.

- 27 -

- The term "substantially purified" as used herein refers to a molecule, such as a peptide that is substantially free of other proteins, lipids, carbohydrates, nucleic acids, and other biological materials with which it is naturally associated. For example, a substantially pure molecule, such as a polypeptide, can be at least 60%, by dry weight, the molecule of interest. One skilled in the art can purify GDF receptors peptides using standard protein purification methods and the purity of the polypeptides can be determined using standard methods including, *e.g.*, polyacrylamide gel electrophoresis (*e.g.*, SDS-PAGE), column chromatography (*e.g.*, high performance liquid chromatography (HPLC)), and amino-terminal amino acid sequence analysis.
- 10 Non-peptide compounds that mimic the binding and function of GDF receptors ("mimetics") can be produced by the approach outlined in Saragovi *et al.*, *Science* 253: 792-95 (1991). Mimetics are molecules which mimic elements of protein secondary structure. See, for example, Johnson *et al.*, "Peptide Turn Mimetics," in BIOTECHNOLOGY AND PHARMACY, Pezzuto *et al.*, Eds., (Chapman and Hall, New York 1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions. For the purposes of the present invention, appropriate mimetics can be considered to be the equivalent of GDF receptors itself.

- Longer peptides can be produced by the "native chemical" ligation technique which links together peptides (Dawson, *et al.*, *Science*, 266:776, 1994). Variants can be created by recombinant techniques employing genomic or cDNA cloning methods. Site-specific and region-directed mutagenesis techniques can be employed. See CURRENT PROTOCOLS IN MOLECULAR BIOLOGY vol. 1, ch. 8 (Ausubel *et al.* eds., J. Wiley & Sons 1989 & Supp. 1990-93); PROTEIN ENGINEERING (Oxender & Fox eds., A. Liss, Inc. 1987). In addition, linker-scanning and PCR-mediated techniques can be employed for mutagenesis. See PCR TECHNOLOGY (Erlich ed., Stockton Press 1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vols. 1 & 2, *supra*. Protein sequencing, structure and modeling approaches for use with any of the above techniques

- 28 -

are disclosed in PROTEIN ENGINEERING, *loc. cit.*, and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vols. 1 & 2, *supra*.

GDF RECEPTOR-BINDING AND BLOCKING AGENTS

In yet another embodiment, the present invention relates to GDF receptor-binding agents
5 that block binding of GDFs to their receptors. Such agents could represent research and
diagnostic tools in the study of muscle wasting disorder as described above and the
development of more effective therapeutics. In addition, pharmaceutical compositions
comprising GDF receptor-binding agents may represent effective therapeutics. In the
context of the invention, the phrase "GDF receptor-binding agent" denotes a naturally
10 occurring ligand of GDF receptors such as, for example: GDF-1-16; a synthetic ligand
of GDF receptors, or appropriate derivatives of the natural or synthetic ligands. The
determination and isolation of ligands is well described in the art. *See, e.g.,* Lerner,
Trends NeuroSci. 17:142-146 (1994) which is hereby incorporated in its entirety by
reference.

15 In yet another embodiment, the present invention relates to GDF receptor-binding agents
that interfere with binding between GDF receptor and a GDF. Such binding agents may
interfere by competitive inhibition, by non-competitive inhibition or by uncompetitive
inhibition. Interference with normal binding between GDF receptors and one or more
GDF can result in a useful pharmacological effect.

SCREEN FOR BINDING AND BLOCKING COMPOSITIONS

In another embodiment, the invention provides a method for identifying a composition
which binds to GDF receptors. The method includes incubating components comprising
the composition and GDF receptors under conditions sufficient to allow the components
to interact and measuring the binding of the composition to GDF receptors.
25 Compositions that bind to GDF receptors include peptides, peptidomimetics,
polypeptides, chemical compounds and biologic agents as described above.

- 29 -

Incubating includes conditions which allow contact between the test composition and GDF receptors. Contacting includes in solution and in solid phase. The test ligand(s)/composition may optionally be a combinatorial library for screening a plurality of compositions. Compositions identified in the method of the invention can be further
5 evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction (Saiki, *et al.*, *Bio/Technology*, 3:1008-1012, 1985), allele-specific oligonucleotide (ASO) probe analysis (Conner, *et al.*, *Proc. Natl. Acad. Sci. USA*, 80:278, 1983), oligonucleotide ligation assays (OLAs) (Landegren, *et*
10 *al.*, *Science*, 241:1077, 1988), and the like. Molecular techniques for DNA analysis have been reviewed (Landegren, *et al.*, *Science*, 242:229-237, 1988).

To determine if a composition can functionally complex with the receptor protein, induction of the exogenous gene is monitored by monitoring changes in the protein levels of the protein encoded for by the exogenous gene, for example. When a composition(s)
15 is found that can induce transcription of the exogenous gene, it is concluded that this composition(s) can bind to the receptor protein coded for by the nucleic acid encoding the initial sample test composition(s).

Expression of the exogenous gene can be monitored by a functional assay or assay for a protein product, for example. The exogenous gene is therefore a gene which will
20 provide an assayable/measurable expression product in order to allow detection of expression of the exogenous gene. Such exogenous genes include, but are not limited to, reporter genes such as chloramphenicol acetyltransferase gene, an alkaline phosphatase gene, beta-galactosidase, a luciferase gene, a green fluorescent protein gene, guanine xanthine phosphoribosyltransferase, alkaline phosphatase, and antibiotic
25 resistance genes (e.g., neomycin phosphotransferase).

Expression of the exogenous gene is indicative of composition-receptor binding, thus, the binding or blocking composition can be identified and isolated. The compositions

- 30 -

of the present invention can be extracted and purified from the culture media or a cell by using known protein purification techniques commonly employed, such as extraction, precipitation, ion exchange chromatography, affinity chromatography, gel filtration and the like. Compositions can be isolated by affinity chromatography using the modified
5 receptor protein extracellular domain bound to a column matrix or by heparin chromatography.

Also included in the screening method of the invention is combinatorial chemistry methods for identifying chemical compounds that bind to GDF receptors. Thus, the screening method is also useful for identifying variants, binding or blocking agents, etc.,
10 which functionally, if not physically (*e.g.*, sterically) act as antagonists or agonists, as desired.

EXAMPLES

Distribution of receptors for GDF-8 and GDF-11.

The purified GDF-8 and GDF-11 proteins will be used primarily to assay for biological
15 activities. In order to identify potential target cells for GDF-8 and GDF-11 action cells expressing their receptors will be searched. For this purpose, the purified protein will be radioiodinated using the chloramine T method, which has been used successfully to label other members of this superfamily, like TGF- β (Cheifetz *et al.*, 1987), activins (Sugino *et al.*, 1988), and BMPs (Paralkar *et al.*, 1991), for receptor-binding studies. The
20 mature processed forms of GDF-8 and GDF-11 each contain multiple tyrosine residues. Two different approaches will then be taken to attempt to identify receptors for these proteins.

One approach will be taken to determine the number, affinity, and distribution of receptors. Either whole cells grown in culture, frozen sections of embryos or adult
25 tissues, or total membrane fractions prepared from tissues or cultured cells will be incubated with the labeled protein, and the amount or distribution of bound protein will be determined. For experiments involving cell lines or membranes, the amount of

- 31 -

binding will be determined by measuring either the amount of radioactivity bound to cells on the dish after several washes or, in the case of membranes, the amount of radioactivity sedimented with the membranes after centrifugation or retained with the membranes on a filter. For experiments involving primary cultures, where the number
5 of cells may be more limited, binding sites will be visualized directly by overlaying with photographic emulsion. For experiments involving frozen sections, sites of ligand binding will be visualized by exposing these sections to high resolution Beta-max hyperfilm; if finer localization is required, the sections will be dipped in photographic emulsion. For all of these experiments, specific binding will be determined by adding
10 excess unlabeled protein as competitor (for example, see Lee and Nathans, 1988).

A second approach will also be taken to begin to characterize the receptor biochemically. Membrane preparations or potential target cells grown in culture will be incubated with labeled ligand, and receptor/ligand complexes will be covalently cross-linked using disuccinimidyl suberate, which has been commonly used to identify receptors for a
15 variety of ligands, including members of the TGF- β superfamily (for example, see Massague and Like, 1985). Cross-linked complexes will then be electrophoresed on SDS polyacrylamide gels to look for bands labeled in the absence but not in the presence of excess unlabeled protein. The molecular weight of the putative receptor will be estimated by subtracting the molecular weight of the ligand. An important question that
20 these experiments will address is whether GDF-8 and GDF-11 signal through type I and type II receptors like many other members of the TGF- β superfamily (for review, see Massague, 1996).

Once a method for detecting receptors for these molecules has been achieved, more detailed analysis will be carried out to determine the binding affinities and specificities.
25 A Scatchard analysis will be used to determine the number of binding sites and dissociation constants. By carrying out cross-competition analyses between GDF-8 and GDF-11 (see Figures 1 and 2, respectively for nucleotide and amino acid sequences), it will be possible to determine whether they are capable of binding to the same receptor

- 32 -

and their relative affinities. These studies will be critical as they will give an indication as to whether the molecules signal through the same or different receptors. Competition experiments using other TGF- β family members will be performed to determine specificity. Some of these ligands are available commercially, and some others are
5 available from Genetics Institute, Inc.

For these experiments, a variety of embryonic and adult tissues and cell lines will be tested. Based on the specific expression of GDF-8 in skeletal muscle and the phenotype of GDF-8 knock-out mice, initial studies focus on embryonic and adult muscle tissue for membrane preparation and for receptor studies using frozen sections. In addition,
10 myoblasts will be isolated and cultured from embryos at various days of gestation or satellite cells from adult muscle as described (Vivarelli and Cossu, 1986; Cossu et al., 1980). The binding studies on these primary cells after various days in culture will be performed and binding sites localized by autoradiography so that the binding sites can be co-localized with various myogenic markers, such as muscle myosin (Vivarelli et al.,
15 1988), and correlate binding with the differentiation state of the cells, such as formation of multinucleated myotubes. In addition to using primary cells, cell lines will be utilized to look for receptors. In particular, the initial focus will be on three cell lines, C2C12, L6, and P19. C2C12 and L6 myoblasts will differentiate spontaneously in culture and form myotubes depending on the particular growth conditions (Yaffe and Saxel, 1977;
20 Yaffe, 1968). P19 embryonal carcinoma cells can be induced to differentiate into various cell types, including skeletal muscle cells in the presence of DMSO (Rudnicki and McBurney, 1987). Receptor binding studies will be carried out on these cell lines under various growth conditions and at various stages of differentiation.

Although the initial studies will focus on muscle cells, other tissues and cell types will
25 be examined for the presence of GDF-8 and GDF-11 receptors.

Recombinant human GDF-8 homodimer was used in these binding studies. The rh-GDF-8 was expressed using CHO cells and purified to approximately 90% purity. The

- 33 -

autoradiograph (Figure 5) shows that the GDF-8 has the expected 25-27 KD molecular weight and upon reduction is reduced to the 12KD monomer. Using I-125 labeled GDF-8 in a receptor-ligand binding assay, two myoblast cell lines, L6 and G-8, were found to bind GDF-8. The binding was specific since non labeled GDF-8 effectively competed the binding of the labeled ligand. These results are illustrated in Figures 6 and 7, respectively. The dissociation constant (K_d) is 370 pM and L6 myoblasts have a high number (5,000 receptors/cell) of cell surface binding proteins (Figure 6). GDF-11 (also called BMP-11) is highly homologous (>90%) to GDF-8. Receptor binding studies were performed to determine if GDF-11 also binds the GDF-8 receptor. Figure 6 shows that GDF-8 and GDF-11 do bind to the same binding proteins on L6 myoblasts. It is important to establish whether or not GDF-8 binds to the known TGF- β receptor. As shown in Figure 6, TGF- β does not compete the binding of GDF-8, indicating that the GDF-8 receptor is distinct from the TGF- β receptor. The GDF-8 receptor is not expressed on all myoblast cell lines. Figures 8-11 are examples of four myoblast cell lines (C2C12, G7, MLB13MYC c14 and BC3H1) which do not bind GDF-8.

Cloning the gene or genes encoding receptors for GDF-8 and GDF-11.

As a first step towards understanding the mechanism by which GDF-8 and GDF-11 exert their biological effects, it is important to clone the genes encoding their receptors. From the experiments above, it will be more clear as to whether GDF-8 and GDF-11 bind to the same receptor or to different receptors. There will also be considerable information regarding the tissue and cell type distribution of these receptors. Using this information, two different approaches will be taken to clone the receptor genes.

The first approach will be to use an expression cloning strategy. In fact, this was the strategy that was originally used by Mathews and Vale (1991) and Lin et al. (1992) to clone the first activin and TGF- β receptors. We will begin by preparing poly A-selected RNA from the tissue or cell type that expresses the highest relative number of high affinity binding sites. We will then use this RNA to prepare a cDNA library in the mammalian expression vector pcDNA-1. This vector contains a CMV promoter and an

- 34 -

- SV40 origin of replication. The library will be plated, and cells from each plate will be pooled into broth and frozen. Aliquots from each pool will then be grown for preparation of DNA. Each individual pool will be transiently transfected into COS cells in chamber slides, and transfected cells will be incubated with iodinated GDF-8 or GDF-11. After
- 5 washing away the unbound protein, the sites of ligand binding will be visualized by autoradiography. Once a positive pool is identified, the cells from that pool will be replated at lower density, and the process will be repeated. Positive pools will then be plated, and individual colonies will be picked into grids and re-analyzed as described (Wong et al., 1985).
- 10 We will attempt to carry out this screen initially using pool sizes of 1500 colonies. In order to be certain that we will be able to identify a positive clone in a mixture of this complexity, we will carry out a control experiment using TGF- β and a cloned type II receptor. The coding sequence for the TGF- β type II receptor will be cloned into the pcDNA-1 vector, and bacteria transformed with this construct will be mixed with
- 15 bacteria from our library at various ratios, including 1:1500. We will then transfect DNA prepared from this mixture into COS cells, incubate with iodinated TGF- β , and visualize by autoradiography. If we can see positive signals at a ratio of 1:1500, we will begin screening pools of 1500 clones. Otherwise, we will use smaller pool sizes corresponding to ratios at which the procedure is sensitive enough to identify a positive signal in our
- 20 control experiments. While we have no previous experience in expression cloning per se, we have constructed over 50 cDNA libraries in the past, and many of these have yielded a high frequency of full-length cDNA clones.

- We will also use a second parallel strategy to attempt to clone the GDF-8 and GDF-11 receptors. We will take advantage of the fact that most receptors for members of the
- 25 TGF- β superfamily that have been identified belong to the membrane-spanning serine/threonine kinase family (for review, see Massague, 1996). Because the cytoplasmic domains of these receptors are related in sequence, we will attempt to use degenerate PCR to clone members of this receptor family that are expressed in tissues

- 35 -

that contain binding sites for GDF-8 and GDF-11. In fact, this is the approach that has been used to identify most of the members of this receptor family. We have extensive experience using this type of strategy for identifying ligands in this superfamily, and therefore, we are quite confident that we will be able to carry out this approach

5 successfully. The general strategy will be to design degenerate primers corresponding to conserved regions of the known receptors, to use these primers for PCR on cDNA prepared from the appropriate RNA samples (most likely from skeletal muscle), to subclone the PCR products, and finally to sequence individual subclones. As sequences are identified, they will be used as hybridization probes to eliminate duplicate clones

10 from further analysis. We will then test the receptors that we identify for their ability to bind purified GDF-8 and GDF-11. Because this screen will yield only small PCR products, we will obtain full-length cDNA clones for each receptor from cDNA libraries prepared from the appropriate tissue, insert these cDNA clones into the pcDNA-1 vector, transfect these constructs into COS cells, and assay the transfected cells for their ability

15 to bind iodinated GDF-8 or GDF-11. Ideally, we would like to test every receptor that we identify in this screen for their ability to bind these ligands. However, the number of receptors that we identify may be large, and isolating all of the full-length cDNAs and testing them may require considerable effort. Almost certainly some of the receptors that we identify will correspond to known receptors, and for these, either obtaining full-length

20 cDNA clones from other investigators or amplifying the coding sequences by PCR based on the published sequences should be straightforward. For novel sequences, we will determine their tissue distribution by Northern analysis and then give the highest priority to those receptors whose expression pattern most closely resembles the distribution of GDF-8 and/or GDF-11 binding sites as determined above.

25 In particular, it is known that these receptors fall into two classes, type I and type II, which can be distinguished based on the sequence and which are both required for full activity. Certain ligands cannot bind type I receptors in the absence of type II receptors while others are capable of binding both receptor types (for review, see Massague, 1996). The cross-linking experiments outlined above should give some indication as to whether

- 36 -

both type I and type II receptors are also involved in signalling GDF-8 and GDF-11. If so, it will be important to clone both of these receptor subtypes in order to fully understand how GDF-8 and GDF-11 transmit their signals. Because we cannot predict whether the type I receptor is capable of interacting with GDF-8 and GDF-11 in the
5 absence of the type II receptor, we will focus first on cloning the type II receptor(s). Only after we have at least one type II receptor for these ligands in hand will we attempt to identify the type I receptors for GDF-8 and GDF-11. Our general strategy will be to co-transfect the type II receptor with each of the type I receptors that we identify in the PCR screen and then assay the transfected cells by crosslinking as described in Specific
10 Aim 4. If the type I receptor is part of the receptor complex for GDF-8 or GDF-11, we should be able to detect two cross-linked receptor species in the transfected cells, one corresponding to the type I receptor and the other corresponding to the type II receptor.

The search for GDF-8 and GDF-11 receptors is further complicated by the fact at least one member of the TGF- β superfamily, namely, GDNF, is capable of signalling through
15 a completely different type of receptor complex involving a GPI-linked component (GDNFR-alpha) and a receptor tyrosine kinase (c-ret) (Trupp et al., 1996; Durbec et al., 1996; Treanor et al., 1996; Jing et al., 1996). Although GDNF is the most distantly-related member of the TGF- β superfamily, it is certainly possible that other TGF- β family members may also signal through an analogous receptor system. If GDF-8
20 and GDF-11 do signal through a similar receptor complex, our expression screening approach should be able to identify at least the GPI-linked component (indeed GDNFR-alpha was identified using an expression screening approach) of this complex. However, identifying the analogous receptor tyrosine kinase would probably require a substantial amount of additional work, such as biochemical purification of the complex.
25 In the case of GDNF, the similar phenotypes of GDNF- and c-ret-deficient mice suggested c-ret as a potential receptor for GDNF.

- 37 -

GDF-11 Transgenic Knockout Mice

The phenotype of GDF-11 knockout mice in several respects resembles the phenotype of mice carrying a deletion of a receptor for some members of the TGF- β superfamily, the activin type IIB receptor (ActRIIB). To determine the biological function of GDF-11, we disrupted the GDF-11 gene by homologous targeting in embryonic stem cells. A murine 129 SV/J genomic library was prepared in lambda FIXII according to the instructions provided by Stratagene (La Jolla, CA). The structure of the GDF-11 gene was deduced from restriction mapping and partial sequencing of phage clones isolated from the library. Vectors for preparing the targeting construct were kindly provided by Philip Soriano and Kirk Thomas. To ensure that the resulting mice would be null for GDF-11 function, the entire mature C-terminal region was deleted and replaced by a neo cassette (Figure 12a,b). R1 ES cells were transfected with the targeting construct, selected with gancyclovir (2 μ M) and G418 (250 μ g/ml), and analyzed by Southern analysis. Homologous targeting of the GDF-11 gene was seen in 8/155 g-
gancyclovir/G418 doubly resistant ES cell clones. Following injection of several targeted clones into C57BL/6J blastocysts, we obtained chimeras from one ES clone that produced heterozygous pups when crossed to both C57BL/6J and 129/SvJ females. Crosses of C57BL/6J/129/SvJ hybrid F1 heterozygotes produced 49 wild-type (34%), 94 heterozygous (66%) and no homozygous mutant adult offspring. Similarly, there were no adult homozygous null animals seen in the 129/SvJ background (32 wild-type (36%) and 56 heterozygous mutant (64%) animals).

To determine the age at which homozygous mutants were dying, we genotyped litters of embryos isolated at various gestational ages from heterozygous females that had been mated to heterozygous males. At all embryonic stages examined, homozygous mutant embryos were present at approximately the predicted frequency of 25%. Among hybrid newborn mice, the different genotypes were also represented at the expected Mendelian ratio of 1:2:1 (34 +/+ (28%), 61 +/- (50%), and 28 -/- (23%)). Homozygous mutant mice were born alive and were able to breath and nurse. All homozygous mutants died, however, within the first 24 hours after birth. The precise cause of death was unknown,

- 38 -

but the lethality may have been related to the fact that the kidneys in homozygous mutants were either severely hypoplastic or completely absent. A summary of the kidney abnormalities in these mice is shown in Figure 13.

Anatomical Differences In Knockout Mice

- 5 Homozygous mutant animals were easily recognizable by their severely shortened or absent tails (Figure 14a). To further characterize the tail defects in these homozygous mutant animals, we examined their skeletons to determine the degree of disruption of the caudal vertebrae. A comparison of wild-type and mutant skeleton preparations of late stage embryos and newborn mice, however, revealed differences not only in the caudal
10 region of the animals but in many other regions as well. In nearly every case where differences were noted, the abnormalities appeared to represent homeotic transformations of vertebral segments in which particular segments appeared to have a morphology typical of more anterior segments. These transformations, which are summarized in Figure 15, were evident throughout the axial skeleton extending from the cervical region
15 to the caudal region. Except for the defects seen in the axial skeleton, the rest of the skeleton, such as the cranium and limb bones, appeared normal.

Anterior transformations of the vertebrae in mutant newborn animals were most readily apparent in the thoracic region, where there was a dramatic increase in the number of thoracic (T) segments. All wild-type mice examined showed the typical pattern of 13
20 thoracic vertebrae each with its associated pair of ribs (Figure 14(b,e)). In contrast, homozygous mutant mice showed a striking increase in the number of thoracic vertebrae. All homozygous mutants examined had 4 to 5 extra pairs of ribs for a total of 17 to 18 (Figure 14(d,g)) although in over 1/3 of these animals, the 18th rib appeared to be rudimentary. Hence, segments that would normally correspond to lumbar (L) segments
25 L1 to L4 or L5 appeared to have been transformed into thoracic segments in mutant animals.

- 39 -

Moreover, transformations within the thoracic region in which one thoracic vertebra had a morphology characteristic of another thoracic vertebra were also evident. For example, in wild-type mice, the first 7 pairs of ribs attach to the sternum, and the remaining 6 are unattached or free (Figure 14(e,h)). In homozygous mutants, there was an increase in the
5 number of both attached and free pairs of ribs to 10-11 and 7-8, respectively (Figure 14(g,j)). Therefore, thoracic segments T8, T9, T10, and in some cases even T11, which all have free ribs in wild-type animals, were transformed in mutant animals to have a characteristic typical of more anterior thoracic segments, namely, the presence of ribs attached to the sternum. Consistent with this finding, the transitional spinous process and
10 transitional articular processes which are normally found on T10 in wild-type animals were instead found on T13 in homozygous mutants (data not shown). Additional transformations within the thoracic region were also noted in certain mutant animals. For example, in wild-type mice, the ribs derived from T1 normally touch the top of the sternum. However, in 2/23 hybrid and 2/3 129/SvJ homozygous mutant mice examined,
15 T2 appeared to have been transformed to have a morphology resembling that of T1; that is, in these animals, the ribs derived from T2 extended to touch the top of the sternum. In these cases, the ribs derived from T1 appeared to fuse to the second pair of ribs. Finally, in 82% of homozygous mutants, the long spinous process normally present on T2 was shifted to the position of T3. In certain other homozygous mutants, asymmetric
20 fusion of a pair of vertebrosteral ribs was seen at other thoracic levels.

The anterior transformations were not restricted to the thoracic region. The anterior most transformation that we observed was at the level of the 6th cervical vertebra (C6). In wild-type mice, C6 is readily identifiable by the presence of two anterior tuberculi on the ventral side. In several homozygous mutant mice, although one of these two anterior
25 tuberculi was present on C6, the other was present at the position of C7 instead. Hence, in these mice, C7 appeared to have been partially transformed to have a morphology resembling that of C6. One other homozygous mutant had 2 anterior tuberculi on C7 but retained one on C6 for a complete C7 to C6 transformation but a partial C6 to C5 transformation.

- 40 -

Transformations of the axial skeleton also extended into the lumbar region. Whereas wild-type animals normally have only 6 lumbar vertebrae, homozygous mutants had 8-9. At least 6 of the lumbar vertebrae in the mutants must have derived from segments that would normally have given rise to sacral and caudal vertebrae as the data described
5 above suggest that 4 to 5 lumbar segments were transformed into thoracic segments. Hence, homozygous mutant mice had a total of 33-34 presacral vertebrae compared to 26 presacral vertebrae normally present in wild-type mice. The most common presacral vertebral patterns were C7/T18/L8 and C7/T18/L9 for mutant mice compared to C7/T13/L6 for wild-type mice. The presence of additional presacral vertebrae in mutant
10 animals was obvious even without detailed examination of the skeletons as the position of the hindlimbs relative to the forelimbs was displaced posteriorly by 7-8 segments.

Although the sacral and caudal vertebrae were also affected in homozygous mutant mice, the exact nature of each transformation was not as readily identifiable. In wild-type mice, sacral segments S1 and S2 typically have broad transverse processes compared to
15 S3 and S4. In the mutants, there did not appear to be an identifiable S1 or S2 vertebra. Instead, mutant animals had several vertebrae that appeared to have morphology similar to S3. In addition, the transverse processes of all 4 sacral vertebrae are normally fused to each other although in newborns often only fusions of the first 3 vertebrae are seen. In homozygous mutants, however, the transverse processes of the sacral vertebrae were
20 usually unfused. In the caudalmost region, all mutant animals also had severely malformed vertebrae with extensive fusions of cartilage. Although the severity of the fusions made it difficult to count the total number of vertebrae in the caudal region, we were able to count up to 15 transverse processes in several animals. We were unable to determine whether these represented sacral or caudal vertebrae in the mutants because
25 we could not establish morphologic criteria for distinguishing S4 from caudal vertebrae even in wild-type newborn animals. Regardless of their identities, the total number of vertebrae in this region was significantly reduced from the normal number of approximately 30. Hence, although the mutants had significantly more thoracic and

- 41 -

lumber vertebrae than wild-type mice, the total number of segments was reduced in the mutants due to the truncation of the tails.

Heterozygous mice also showed abnormalities in the axial skeleton although the phenotype was much milder than in homozygous mice. The most obvious abnormality
5 in heterozygous mice was the presence of an additional thoracic segment with an associated pair of ribs (Figure 14(c,f)). This transformation was present in every heterozygous animal examined, and in every case, the additional pair of ribs was attached to the sternum (Figure 14(i)). Hence, T8, whose associated rib normally does not touch the sternum, appeared to have been transformed to a morphology characteristic of a more
10 anterior thoracic vertebra, and L1 appeared to have been transformed to a morphology characteristic of a posterior thoracic vertebra. Other abnormalities indicative of anterior transformations were also seen to varying degrees in heterozygous mice. These included a shift of the long spinous process characteristic of T2 by one segment to T3, a shift of the articular and spinous processes from T10 to T11, a shift of the anterior tuberculus on
15 C6 to C7, and transformation of T2 to T1 where the rib associated with T2 touched the top of the sternum.

In order to understand the basis for the abnormalities in axial patterning seen in GDF-11 mutant mice, we examined mutant embryos isolated at various stages of development and compared them to wild-type embryos. By gross morphological examination,
20 homozygous mutant embryos isolated up to day 9.5 of gestation were not readily distinguishable from corresponding wild-type embryos. In particular, the number of somites present at any given developmental age was identical between mutant and wild-type embryos, suggesting that the rate of somite formation was unaltered in the mutants. By day 10.5-11.5 p.c., mutant embryos could be easily distinguished from
25 wild-type embryos by the posterior displacement of the hindlimb by 7-8 somites. The abnormalities in tail development were also readily apparent at this stage. Taken together, these data suggest that the abnormalities observed in the mutant skeletons

- 42 -

represented true transformations of segment identities rather than the insertion of additional segments, for example, by an enhanced rate of somitogenesis.

Alterations in expression of homeobox containing genes are known to cause transformations in *Drosophila* and in vertebrates. To see if the expression patterns of Hox genes (the vertebrate homeobox containing genes) were altered in GDF-11 null mutants we determined the expression pattern of 3 representative Hox genes, Hoxc-6, Hoxc-8 and Hoxc-11, in day 12.5 p.c. wild-type, heterozygous and homozygous mutant embryos by whole mount in situ hybridization. The expression pattern of Hoxc-6 in wild-type embryos spanned prevertebrae 8-15 which correspond to thoracic segments T1-T8. In homozygous mutants, however, the Hoxc-6 expression pattern was shifted posteriorly and expanded to prevertebrae 9-18 (T2-T11). A similar shift was seen with the Hoxc-8 probe. In wild-type embryos, Hoxc-8 was expressed in prevertebrae 13-18 (T6-T11) but, in homozygous mutant embryos, Hoxc-8 was expressed in prevertebrae 14-22 (T7-T15). Finally, Hoxc-11 expression was also shifted posteriorly in that the anterior boundary of expression changed from prevertebrae 28 in wild-type embryos to prevertebrae 36 in mutant embryos. (Note that because the position of the hindlimb is also shifted posteriorly in mutant embryos, the Hoxc-11 expression patterns in wild-type and mutant appeared similar relative to the hindlimbs). These data provide further evidence that the skeletal abnormalities seen in mutant animals represent homeotic transformations.

The phenotype of GDF-11 mice suggested that GDF-11 acts early during embryogenesis as a global regulator of axial patterning. To begin to examine the mechanism by which GDF-11 exerts its effects, we determined the expression pattern of GDF-11 in early mouse embryos by whole mount in situ hybridization. At these stages the primary sites of GDF-11 expression correlated precisely with the known sites at which mesodermal cells are generated. Expression of GDF-11 was first detected at day 8.25-8.5 p.c. (8-10 somites) in the primitive streak region, which is the site at which ingressing cells form the mesoderm of the developing embryo. Expression was maintained in the primitive

- 43 -

streak at day 8.75, but by day 9.5 p.c., when the tail bud replaces the primitive streak as the source of new mesodermal cells, expression of GDF-11 shifted to the tail bud. Hence at these early stages, GDF-11 appears to be synthesized in the region of the developing embryo where new mesodermal cells arise and presumably acquire their positional
5 identity.

The phenotype of GDF-11 knockout mice in several respects resembles the phenotype of mice carrying a deletion of a receptor for some members of the TGF- β superfamily, the activin type IIB receptor (ActRIIB). As in the case of GDF-11 knockout mice, the ActRIIB knockout mice have extra pairs of ribs and a spectrum of kidney defects ranging
10 from hypoplastic kidneys to complete absence of kidneys. The similarity in the phenotypes of these mice raises the possibility that ActRIIB may be a receptor for GDF-11. However, ActRIIB may not be the sole receptor for GDF-11 because the phenotype of GDF-11 knockout mice is more severe than the phenotype of ActRIIB mice. For example, whereas the GDF-11 knockout animals have 4-5 extra pairs of ribs
15 and show homeotic transformations throughout the axial skeleton, the ActRIIB knockout animals have only 3 extra pairs of ribs and do not show transformations at other axial levels. In addition, the data indicate that the kidney defects in the GDF-11 knockout mice are also more severe than those in ActRIIB knockout mice. The ActRIIB knockout mice show defects in left/right axis formation, such as lung isomerism and a range of
20 heart defects that we have not yet observed in GDF-11 knockout mice. ActRIIB can bind the activins and certain BMPs, although none of the knockout mice generated for these ligands show defects in left/right axis formation.

If GDF-11 does act directly on mesodermal cells to establish positional identity, the data presented here would be consistent with either short range or morphogen models for
25 GDF-11 action. That is, GDF-11 may act on mesodermal precursors to establish patterns of Hox gene expression as these cells are being generated at the site of GDF-11 expression, or alternatively, GDF-11 produced at the posterior end of the embryo may diffuse to form a morphogen gradient. Whatever the mechanism of action of GDF-11

- 44 -

may be, the fact that gross anterior/posterior patterning still does occur in GDF-11 knockout animals suggests that GDF-11 may not be the sole regulator of anterior/posterior specification. Nevertheless, it is clear that GDF-11 plays an important role as a global regulator of axial patterning and that further study of this molecule will
5 lead to important new insights into how positional identity along the anterior/posterior axis is established in the vertebrate embryo.

Similar phenotypes are expected in GDF-8 knockout animals. For example, GDF-8 knockout animals are expected to have increased number of ribs, kidney defects and anatomical differences when compared to wild-type.

10 LITERATURE CITED

Baker, J., J. P. Liu, E. J. Robertson and A. Efstratiadis (1993). "Role of insulin-like growth factors in embryonic and postnatal growth." *Cell* 75: 73-82.

Bladt, F., D. Riethmacher, S. Isenmann, A. Aguzzi and C. Birchmeier (1995). "Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb
15 bud." *Nature* 376: 768-771.

Bullough, W. S. (1965). "Mitotic and functional homeostasis: A speculative review." *Cancer Res* 25: 1683-1727.

Cheifetz, S., J. A. Weatherbee, M. L.-S. Tsang, J. K. Anderson, J. E. Mole, R. Lucas and J. Massague (1987). "The transforming growth factor- β system, a complex pattern of
20 cross-reactive ligands and receptors." *Cell* 48: 409-415.

Coleman, M. E., F. DeMayo, K. D. Yin, H. M. Lee, R. Geske, C. Montgomery and R. J. Schwartz (1995). "Myogenic vector expression of insulin-like growth factor I

- 45 -

stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice." *J Biol Chem* 270: 12109-12116.

Colosi, P., J. J. Swiergiel, E. L. Wilder, A. Oviedo and D. I. H. Linzer (1988). "Characterization of proliferin-related protein." *Mol Endocrinol* 2: 579-586.

- 5 Cossu, G., B. Zani, M. Coletta, M. Bouche, M. Pacifici and M. Molinaro (1980). "In vitro differentiation of satellite cells isolated from normal and dystrophic mammalian muscles. A comparison with embryonic myogenic cells." *Cell Differentiation* 9: 3-57-368.

- Cumming, W.J.K., J. Fulthorpe, P. Hudgson and M. Mahon (1994). *Color Atlas of*
10 *Muscle Pathology*, 184-185 (Times Mirror International Publishers Limited, London)

DiMario, J. and R. C. Strohman (1988). "Satellite cells from dystrophic (mdx) mouse muscle are stimulated by fibroblast growth factor in vitro." *Differentiation* 39: 42-49.

- Durbec, P., C. V. Marcos-Gutierrez, C. Kilkenny, M. Grigoriou, K. Wartowaara, P. Suvanto, D. Smith, B. Ponder, F. Costantini, M. Saarma, H. Sariola and V. Pachnis
15 (1996). "GDNF signalling through the Ret receptor tyrosine kinase." *Nature* 381: 789-793.

Florini, J. R. (1987). "Hormonal control of muscle growth." *Muscle Nerve* 10: 577-598.

Florini, J. R., D. Z. Ewton and K. A. Magri (1991). "Hormones, growth factors, and myogenic differentiation." *Ann Rev Physiol* 53: 201-216.

- 20 Friedman, J. M. and R. L. Leibel (1992). "Tackling a weighty problem." *Cell* 69: 217-220.

- 46 -

Gentry, L. E. and B. W. Nash (1990). "The pro domain of pre-pro-transforming growth factor β 1 when independently expressed is a functional binding protein for the mature growth factor." *Biochem* 29: 6851-6857.

- Gentry, L. E., N. R. Webb, G. J. Lim, A. M. Brunner, J. E. Ranchalis, D. R. Twardzik,
5 M. N. Lioubin, H. Marquardt and A. F. Purchio (1987). "Type 1 transforming growth factor beta: Amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells." *Mol Cell Biol* 7: 3418-3427.

Hamilton, W. G. and R. G. Ham (1977). "Clonal growth of Chinese hamster ovary cell lines in protein-free media." *In Vitro* 13: 537-547.

- 10 Jing, S., D. Wen, Y. Yu, P. L. Holst, Y. Luo, M. Fang, R. Tamir, L. Antonio, Z. Hu, R. Cupples, J.-C. Louis, S. Hu, B. W. Altrock and G. M. Fox (1996). "GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNF- α , a novel receptor for GDNF." *Cell* 85: 1113-1124.

- Lawrence, D. A., R. Pircher and P. Jullien (1985). "Conversion of a high molecular
15 weight latent β -TGF from chicken embryo fibroblasts into a low molecular weight active β -TGF under acidic conditions." *Biochem Biophys Res Comm* 133: 1026-1034.

Lee, S.-J. and D. Nathans (1988). "Proliferin secreted by cultured cells binds to mannose-6-phosphate receptors." *J Biol Chem* 263: 3521-3527.

- Lin, H. Y., X.-F. Wang, E. Ng-Eaton, R. A. Weinberg and H. F. Lodish (1992).
20 "Expression cloning of the TGF- β type II receptor, a functional transmembrane serine/threonine." *Cell* 68: 775-785.

- 47 -

Liu, J.-P., J. Baker, A.S. Perkins, E.J. Robertson and A. Efstratiadis (1993). "Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)." *Cell* 75:59-72.

Lyons, R. M., J. Keski-Oja and H. L. Moses (1988). "Proteolytic activation of latent
5 transforming growth factor- β from fibroblast-conditioned medium." *J Cell Biol* 106:
1659-1665.

Massague, J. (1996). "TGF β signaling: Receptors, transducers, and Mad proteins." *Cell*
85: 947-950.

Massague, J. and B. Like (1985). "Cellular receptors for type β transforming growth
10 factor." *J Biol Chem* 260: 2636-2645.

Mathews, L. S., R. E. Hammer, R. R. Behringer, A. J. D'Ercole, G. I. Bell, R. L. Brinster
and R. D. Palmiter (1988). "Growth enhancement of transgenic mice expressing human
insulin-like growth factor I." *Endocrinology* 123: 2827-2833.

Mathews, L. S. and W. W. Vale (1991). "Expression cloning of an activin receptor, a
15 predicted transmembrane serine kinase." *Cell* 65: 973-982.

McPherron, A. C. and S.-J. Lee (1996). *The Transforming Growth Factor β Superfamily. Growth Factors and Cytokines in Health and Disease.* D. LeRoith and C. Bondy. Greenwich, CT, JAI Press, Inc. 1B: 357-393.

Miyazono, K., U. Hellman, C. Wernstedt and C.-H. Heldin (1988). "Latent high
20 molecular weight complex of transforming growth factor β 1." *J Biol Chem* 263:
6407-6415.

- 48 -

- Paralkar, V. M., R. G. Hammonds and A. H. Reddi (1991). "Identification and characterization of cellular binding proteins (receptors) for recombinant human bone morphogenetic protein 2b, an initiator of bone differentiation cascade." *Proc Natl Acad Sci, USA* 88: 3397-3401.
- 5 Powell-Braxton, L., P. Hollingshead, C. Warburton, M. Dowd, S. Pitts-Meek, D. Dalton, N. Gillett and T. A. Stewart (1993). "IFG-I is required for normal embryonic growth in mice." *Genes Dev* 7: 2609-2617.
- Rudnicki, M. A. and M. W. McBurney (1987). Cell culture methods and induction of differentiation of embryonal carcinoma cell lines. *Teratocarcinomas and Embryonic Stem*
- 10 *Cells: A Practical Approach*. E. J. Robertson. Cambridge, United Kingdom, IRL Press: 19-49.
- Spiegelman, B. M. and J. S. Flier (1996). "Adipogenesis and obesity: Rounding out the big picture." *Cell* 87: 377-389.
- Sugino, H., T. Nakamura, Y. Hasegawa, K. Miyamoto, M. Igarashi, Y. Eto, H. Shibai
- 15 and K. Titani (1988). "Identification of a specific receptor for erythroid differentiation factor on follicular granulosa cell." *J Biol Chem* 263: 15249-15252.
- Treanor, J. J. S., L. Goodman, F. de Sauvage, D. M. Stome, K. T. Poulsen, C. D. Beck, C. Gray, M. P. Armanini, R. A. Pollock, F. Hefti, H. S. Phillips, A. Goddard, M. W. Moore, A. Buj-Bello, A. M. Davies, N. Asai, M. Takahashi, R. Vandlen, C. E. Henderson
- 20 and A. Rosenthal (1996). "Characterization of a multicomponent receptor for GDNF." *Nature* 382: 80-83.
- Trupp, M., E. Arenas, M. Fainzilber, A.-S. Nilsson, B.-A. Sieber, M. Grigoriou, C. Kilkenny, E. Salazar-Grueso, V. Pachnis, U. Arumae, H. Sariola, M. Saarma and C. F.

- 49 -

Ibanez (1996). "Functional receptor for GDNF encoded by the c-ret proto-oncogene." Nature 381: 785-789.

Vivarelli, E., W. E. Brown, R. G. Whalen and G. Cossu (1988). "The expression of slow myosin during mammalian somitogenesis and limb bud differentiation." J Cell Biol 107:
5 2191-2197.

Vivarelli, E. and G. Cossu (1986). "Neural control of early myogenic differentiation in cultures of mouse somites." Dev Biol 117: 319-325.

Wang, E. A., V. Rosen, J. S. D'Alessandro, M. Bauduy, P. Cordes, T. Harada, D. I. Israel, R. M. Hewick, K. M. Kerns, P. LaPan, D. P. Luxenberg, D. McQuaid, I. K. Moutsatsos,
10 J. Nove and J. M. Wozney (1990). "Recombinant human bone morphogenetic protein induces bone formation." Proc Natl Acad Sci, USA 87: 2220-2224.

- 50 -

- Wilson, C. A., N. di Clemente, C. Ehrenfels, R. B. Pepinsky, N. Josso, B. Vigier and R. L. Cate (1993). "Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor- β superfamily." *Mol Endocrinol* 7: 247-257.
- 5 Wong, G. G., J. S. Witek, P. A. Temple, K. M. Wilkens, A. C. Leary, D. P. Luxenberg, S. S. Jones, E. L. Brown, R. M. Kay, E. C. Orr, C. Shoemaker, D. W. Golde, R. J. Kaufman, R. M. Jewick, E. A. Wang and S. C. Clark (1985). "Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural recombinant proteins." *Science* 228: 810-815.
- 10 Yaffe, D. (1968). "Retention of differentiation potentialities during prolonged cultivation of myogenic cells." *Proc Natl Acad Sci USA* 61: 477-483.
- Yaffe, D. and O. Saxel (1977). "Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle." *Nature* 270: 725-727.

THIS PAGE BLANK (USPTO)

What Is Claimed Is:

1. A recombinant cell line that expresses growth differentiation factor-8 (GDF-8) or growth differentiation factor-11 (GDF-11) receptor polypeptide.
2. The cell line of claim 1, wherein the cell is selected from the group of species consisting of avian, bovine, ovine, piscine, murine, human and porcine.
3. An antibody which specifically binds to growth differentiation factor-8 (GDF-8) receptor polypeptide or fragments thereof.
4. The antibody of claim 7, wherein the antibody is a monoclonal antibody.
5. An antibody which specifically binds to growth differentiation factor-11 (GDF-11) receptor polypeptide or fragments thereof.
6. The antibody of claim 7, wherein the antibody is a monoclonal antibody.
7. An isolated polynucleotide which encodes growth differentiation factor-8 (GDF-8) receptor.
8. An isolated polynucleotide which encodes growth differentiation factor-11 (GDF-11) receptor.
9. An expression vector containing in operable linkage the polynucleotide as in claim 7 or 8.
10. A host cell containing the vector of claim 9.

- 52 -

11. A substantially purified peptide fragment of GDF-8 receptor, wherein the peptide inhibits GDF-8 binding to GDF-8 receptor.
12. A substantially purified peptide fragment of GDF-11, wherein the peptide inhibits GDF-11 binding to GDF-11 receptor.
13. A substantially purified GDF-8-binding agent, wherein the binding agent inhibits GDF-8 binding to GDF-8 receptor.
14. A substantially purified GDF-11-binding agent, wherein the binding agent inhibits GDF-11 binding to GDF-11 receptor.
15. The agent as in claims 13 or 14, wherein the agent is selected from a biologic agent and a chemical compound.
16. The agent as in claims 13 or 14, wherein the agent is a anti-GDF antibody or epitope binding fragment thereof.
17. The agent of claim 16, wherein the antibody is a monoclonal antibody or a polyclonal antibody.
18. A method for inhibiting GDF binding to a GDF receptor comprising contacting GDF-receptor with an anti-GDF-antibody.
19. The method of claim 18, wherein the contacting is by *in vivo* administration to a subject.
20. The method of claim 19, wherein the anti-GDF- antibody is administered by intravenous, intra-muscular or subcutaneous injections.

- 53 -

21. The method of claim 20, wherein the anti-GDF- antibody is administered within a dose range of 0.1 ug/kg to 100 mg/kg.
22. The method of claim 20, wherein the antibody is formulated in a pharmaceutically acceptable carrier.
23. A method for identifying a GDF receptor polypeptide comprising:
 - a) incubating components comprising GDF polypeptide and a cell expressing a receptor or a soluble receptor under conditions sufficient to allow the GDF to bind to the receptor;
 - b) measuring the binding of the GDF polypeptide to the receptor; and
 - c) isolating the receptor.
24. The method of claim 23, wherein the GDF is GDF-8 or GDF-11.
25. A method for identifying a compound which binds to GDF receptor polypeptide comprising:
 - a) incubating components comprising the compound and GDF polypeptide under conditions sufficient to allow the components to interact; and
 - b) measuring the binding or effect of binding of the compound to GDF receptor polypeptide.
26. The method of claim 25, wherein the compound is a peptide.
27. The method of claim 25, wherein the compound is a peptidomimetic.
28. The method of claim 25, wherein the GDF receptor is expressed in a cell.
29. The method of claim 28, wherein the cell is the cell of claim 1.

- 54 -

30. The method of claim 25, wherein measuring the ability of the compound to bind to GDF receptor is by detection of a reporter means.
31. The method of claim 30, wherein the reporter means is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator, or an enzyme.
32. A transgenic non-human animal having a phenotype characterized by expression of GDF-receptor polypeptide, the phenotype being conferred by a transgene contained in the somatic and germ cells of the animal, the transgene comprising a nucleic acid sequence which encodes GDF- receptor polypeptide.
33. The transgenic non-human animal of claim 32, wherein the animal is selected from the group of species consisting of avian, bovine, ovine, piscine, murine, and porcine.
34. A method for producing a transgenic non-human animal having a phenotype characterized by expression of GDF- receptor polypeptide otherwise not naturally occurring in the animal, the method comprising:
 - (a) introducing at least one transgene into a zygote of an animal, the transgene(s) comprising a DNA construct encoding GDF-receptor,
 - (b) transplanting the zygote into a pseudopregnant animal,
 - (c) allowing the zygote to develop to term, and
 - (d) identifying at least one transgenic offspring containing the transgene.

- 55 -

35. The method of claim 34, wherein the introducing of the transgene into the embryo is by introducing an embryonic stem cell containing the transgene into the embryo.
36. The method of claim 34, wherein the introducing of the transgene into the embryo is by infecting the embryo with a retrovirus containing the transgene.
37. A transgenic non-human animal having a transgene disrupting or interfering with expression of GDF-receptor chromosomally integrated into the germ cells of the animal.
38. The transgenic non-human animal of claim 37, wherein the transgene comprises GDF-receptor antisense polynucleotide.
39. A method for inhibiting the expression of GDF-receptor in a cell comprising contacting GDF-receptor with an inhibiting effective amount of an antisense oligonucleotide that binds to a segment of an mRNA transcribed from a GDF-receptor gene, whereby the binding of the antisense to the mRNA segment inhibits GDF-receptor expression.
40. Substantially pure GDF receptor polypeptide.
41. The GDF receptor of claim 40, wherein GDF is GDF-8 or GDF-11.

1	GTCTCTCCGACGGTACATGCCACTAATATTTCACTTCGGATTACTGCAAAAGCAAG	60
61	AAATAAGACACACGGCAAAAAAGATTGTCCGATTTTAAATATGATGCCAAAAGTCCA	120
	M M G K L C	
121	AATGTATGTTTATATTTAGCTGTTTCATGCTGATTCCTGCTGGGCGAGTGGATCTAAATGA	180
	M Y V Y I Y L F M L I A A G F V D L N E	
181	GGGAGTGCAGACAGACAAAAATGTGCAAAAAGAGGGGGTGTGTAATGCATGTGGGTGGAG	240
	G S E R E E N V E K E G L C N A C A W R	
241	ACAAAACAGGAGGTACTTCCAGAAATAGAGGCCATAAAATTCAAAATGCTCAGTAAAGCTGGG	300
	G N T R Y S R I E A I K I G I L S K L R	
301	CGTCCAAACAGCTGCTTAACATCAGCAAGATGCTATAGACAACTTCTGCCAAGAGGGGGG	360
	L E T A F <u>W T H S</u> K G A I R Q L L F R A F	
361	TGCACTCGGGGAAGCTGATGATCATGTAAGAGCTCCAGAGGATGACAGCAGTGATGGCTC	420
	P L R E L I D Q Y D V G R D D S S D G S	
421	TTTGGAGATGAGCATTATACGGTACCGAGGCAAGCAATCATTTACCATGGCTACAGAGTC	480
	L E D D D Y H A T T E T I I I M P T E S	
481	TGACTTTTCTAATGCCAGGGGATGGCAAGGGCAATGTTGCTTTTTTAAATTTAGCTCTAA	540
	D F L M G A D G K P K C C F F K F S S K	
541	AATACAGTACAGCAAGTACTAAAGGGCAAGCTGTGCATATATGTCAGAGGGGTGACAGC	600
	I G Y N K V V K A G L W I Y L R P V K I	
601	TGCTACAGAGTGTGTTGACAAATGCTGAGAGTCACTCAAGGGATGAAAGAGGGTACAG	660
	P T T V F V G I L R L I K F M K D G T R	
661	GTATAGTGGAAATGCCATGCTGTGAAAGTTGACATGAGGGCAGGGAGTGGTATTTGGCAGAG	720
	Y T G I R S L K L D W S F G T G I H G S	
721	TATTGATGTGAGAGAGTGTGCAAAATGGGCTCAAGAGGGTCAATGCCAAGTTAGGCAT	780
	I D V K T Y L Q M W L K G P E S N L G I	
781	TGAAATGCAAGGCTTTGGATGACAATGGGGATGATGCTTGGCTTAAGCTTGGCAGGAGAGG	840
	E I K A L D E N G H D L A V T F P G P G	
841	AGAGAGTGGGCTGAATGGCTTTTTAGAGTCAAGGTGACAGACAGAGCCCAAGAGGTGGGG	900
	E D G L N P F F L E V K V T D T P K <u>R S R</u>	
901	GAGAGAGCTTTGGGCTTGACTGGCATGAGCACTCCAGGAAATGGGGTGGCTGGGGCTAGCC	960
	<u>R</u> I D F G L D C D E H S T E S R C C R Y P	
961	CGTCAAGGTCGATTTTGAAGCCTTTGGATCGGACTGGATTATCGCACCAAAAGATATAA	1020
	L T V D F E A F G W D W I I A P K R Y K	
1021	GGCCAAATTACTGCTCAGGAGAGTGTGAATTTGTGTTTTACAAAAATATCGGCATACTCA	1080
	A N Y C S G E C E F V F L O K Y P H T H	
1081	TCTTGTCGACCAAGCAAGCCCAAGGGCTGAGCAGGGCTTCTGCACTCGGACAAAAAT	1140
	L V H Q A N P R G S A G P C C T F T K M	
1141	GTCTCCCAATTAATATGCTATATTTTAAATGCCAAGACAAATAATATATCGGAAAAATTCG	1200
	S P I N M L Y F H G K E O I I Y G K I F	
1201	AGCCATGGTAGTAGACCCGCTGTGGTGGCTCATGAGCTTTGGATTAGCTAGAAACTTCCG	1260
	A M V V D R C G C S	

FIG. 1a
murine GDF-8

1321 AAGTCATGGAGGTCCTTCCCTCTAATTTGGAAAGTGTGAATTCAGCCACCACAGGCTGTA 1320
1321 GGGCTTGCATATGCTCTAGTAAAGTAAGCACAAGCTACAGTGATCAACTAAAAGAGAGA 1350
1331 ATAGATGCAATCGTTGGCATTCAAGCACCATAATAAGCATACTATAGGATGTTGTATGA 1440
1441 TTTCCAGAGTTTTTGAATAGATGGAGATCAAAATTACATTTATGTCCATATATGTATATT 1500
1501 ACAACTACAAATCTAGCCAGGAGGTGAGAGGCATCTTGTGGTGTGCTGAGTTAGGAGGG 1550
1551 TATGATTAAAGGTAAAGTCTTATTTCTTAACAGTTTCACTTAATATTTACAGAGGAATC 1620
1521 TATATGTAGGCTTTGTAAAGTGTAGGATTGTTATCATTTAAAACATCATGTACACTTAT 1630
1531 ATTTGTATTGTATACTTGTAAAGATAAATTCACAAAGTAGGAATGGGGCTTCACATAG 1740
1741 ACAATGGCATTTCCTATTATAATTCGACAATCCAGCAGGCTGCTAATGGAGTGGTGAATGG 1800
1801 CTCTACTGGAGCTCTCGATAGAACTCTACAAAGTAGGAGTCTCTCTCTGCTGCTGCTG 1850
1851 GTGGATCTGACAGACAGAGAGCACTAAGTGTTCAGAGCAATTTCTTTAAGGAAAGAGAAAT 1920
1921 CTTTTTTTTTAGAGGTCAAGTTTCAAGTCAAGTCAAGCAAGGGGAGTCACTGCTGCAATC 1950
1951 TTAAAAGGCAAGCAAGCACTATTTCATTTTTTAATCTAAATTTCAAAATCACTGTCTGCT 2040
2041 TTATCAGATGGCAATTTTGTGTTAAATAATGGAAATGAGTGGTTCTATCAATATTGTAT 2100
2101 AAAAGACTCTGAAGCAATTACATTTATATAATATGTATACAAATATTGTTTTGTAAATAAG 2150
2151 TGTCTCCTTTTATATTTACTTTGGTATATTTTTACAGTAATCAAAATTCAAATCAATTA 2220
2221 GTACAAAGACATGTCTATCTATCAAAAAGGCTGAGTGGTTCTATTTCAAGCTGAATTAG 2250
2251 CAGATTCAATAGTGGTCTTAAAGTCTGTATGTTAAGATTAGAGGTTATATTACAAATCA 2340
2341 ATTTATGTATTTTTTACATTATCACTTATGTTTTCAAGTGGCTGTATCTATGAATGTG 2400
2401 GCTCCCACTCAAAATTTCAATGCCCCACCATTTTAAAATTACAGCAATTACTAAACATAC 2450
2451 CAACATGTATCTAAAGAAATACAAATATGGTATCTCAATACAGCTACTTTTTTATTTTA 2520
2521 TAATTTGACAAATGAATACATTTCTTTTATTTACTTCAGTTTTATAAATCGAAGCTTTGTT 2550
2551 TATCAAAATGTATTGTACTCATAGCTAAATGAATATTCTTTACATAAAATGTGTAGAA 2640
2641 ACTATAAATTAAGTGTTTTCACATTTTTGAAGGC 2675

FIG.1 b

3/28

1	AGGAAAGTAAAGGAGCAACAGAGACAGAAAAACATTATATTGATTTTAAATCAT	60
	M	
61	GCAAAAGCTCCAGCTGTGTGTTTATATTTACCTGTTTATGCTGATTGTTGCTGGTCCAGT	120
	O K L Q L C V Y I Y L F M L I V A G P V	
121	CGATCTAAATGAGAACAGTGCAGCAAAAGAAAATGTCGAAAAGAGCGGGCTGTGTAAATGC	180
	D L N E N S E G K E N V E K E G L C N A	
181	ATGTACTTCGAGACAAAACACTAAATCTTCAGCAATAGAGCCATTAGATACAAATCCT	240
	C T W R Q N T K S S R I E A I K I Q I L	
241	CAGTAAAGTTCCTGTCTGCAACAGCTCTTAACATCAGCAAGATGTTATAGACAAGCTTTT	300
	S K L R L E T A P N E R S K Q V I R Q L L	
301	ACCCAAAGCTCTCTCCAGCTCCCGCACTGATTGATCAGTATGATGTCAGACGGGATGACAG	360
	P K A P F L R E L I D Q Y Q V Q R Q D S	
361	CAGCGATCGCTCTTTTGGAGATGACGATTATCAGCTACAGCGAAACAATCATTACCAT	420
	S D G S L E D Q D Y H A T T E T I I T M	
421	CGCTACAGAGTCTGATTTTCTAATGCCAGTGGATGCCAAAAGCCAAATGTTGCTTCTTTAA	480
	P T E S O F L M Q V D G K P K C C F F K	
481	ATTTAGCTCTAAATACAAATACATAAAGTAGTAAAGCGGCACTATGGATATATTTGAG	540
	F S S K I Q Y N K V V K A G L H I Y L R	
541	AGCGCTCAGAGCTCTACAGAGTGTGTTGTGCAAAATGCTGACCTCATCAACCTATGAA	600
	P V E T F T T V F V G I L R L I K P M K	
601	AGACCGTACAGCTATACGGAATCGGATCTCTGAAAGTTGACATCAAGCCAGGCACTGG	660
	D G T R Y T G I R S L K L D M N P G T G	
661	TATTTGGCAGAGCAATTGATGTGAGAGAGTGTGCAAAATGGCTCAAGCAAGCTGAATC	720
	I H G S I Q V K T V L Q N H L K Q P E S	
721	CAAGTTAGGCATTCAATATAAAGCTTTAGATCAGAAATGCTGATCTTGGCTGTAGCTT	780
	N L G I E I K A L G E N G H D L A V T E	
781	CCAGGAGCAGGAGAGATGCGGCTGAATCCGTTTTTAGAGCTCAAGGTAAACAGACACAGC	840
	P G P G E D G L N P F L E V K V T D T F	
841	AAAAAGATCCAGAGCGGATTTTGGTCTTCACTGTGATCAGCACTCAACAGCAATCAGGATG	900
	K R S R R Q F G L O C D E H S T E S R C	
901	CTGTGCTTACCGTCTAAGTGTGATTTTGAAGCTTTTGGATGGGATTGGATTATCGCTCC	960
	C R Y P L T V D F E A F G W D W I I A P	
961	TAAAAGATATAAGCGCAATTACTGCTCTCGAGAGTGTGAATTTGTATTTTACAAAAATA	1020
	K R Y K A N Y C S C E C E F V F L O K Y	
1021	TGCTCATACTCATCTGCTACACCAAGCAAAAGCCAGAGGTTGAGAGGGGCTTGGCTGTAC	1080
	P H T H L V H Q A N P R G S A G P C C T	
1081	TGCCAGAAAGATGTCTCCAAATTAATATGCTATATTTTAATGCCAAGGACAAATAATATA	1140
	P T K M S P I N M L Y F H G K E Q I I Y	
1141	TGGGAAAATTCAGCGGATGGTAGACCGCTGTGGGTGCTCATGAGATTTATATTAGC	1200
	G K I P A M V V O R C G C S	

FIG. 1 c

Human GDF-8


```

1201 GTTCATAAGCTTCCATAAACATCGAAGGTTTTCCCGTCACAAATTTGAAAGCTGTCAAATT 1250
1251 AAGTAGCAGAGGCTATAGCGCTAGAGTATCGCTACAGTCAGTTAAGCATAAGCTACAGTAT 1300
1321 GTAAACTAAAAGGGGGAATATATGCAATCGTTGGCATTTAAGCATCCAAACAAATCATAC 1350
1361 AAGAAAGTTTTATGATTTCCAGAGTTTTTGAGCTAGAGGAGATCAAATTACATTTATGT 1400
1441 TCCTATATATTACACATCCCGGAGGAAATGAAAGCGATTCTCCTTGAGTTCTGATGAAT 1500
1501 TAAAGGAGTATCCTTTAAGTCTATTTCTTTAAAGTTTTGTTTTAATATTTACAGAAAAAT 1550
1561 CCACATACAGTATTCGTAAAATGCGAGATTGTTATATACCATCATTCGAATCATCCTTAA 1600
1621 ACGCTTGAATTTATATGTTATGGTAGTATACCTTCGTAAACATAAAATTCACAAAAATAGG 1650
1661 CATCGTGGCAGCATATGCCAATTTCCATTCCATTTATAATTCACACAGTACATTAACAATCC 1700
1741 ATGCCAACCGTGCTAATAGCATAGCGTGAATGCTGAGCGCTACCGAGGTTTATCACATAAA 1800
1801 AAACATTGAGTAAATAGTAGTTCTGTTTTCTGAGAGTGCATTTTCTACAGCTGCAAA 1850
1861 ATGAGCAATGGATTTTCTTTAATGTAAGAAATGATTTTTTCTACAGCTTGGCTTTCAAT 1900
1921 TCTGTAGCATACTTGGAGAAAGTCATTTATCTTAAAGGCGTCAATGGTGTCTTGTCTTT 1950
1981 TATCAAAATGTCAAAATAACATAGCTGGAGAGTAGTAAATTTGTCTTTGCAAAATTAC 2040
2041 AACAGTGGCTTTTGCACAGCTGCAGTTTTTATGCTAAAATAATAGAAATGATCGAGCTGAT 2100
2101 CAATATTGTATAAAAGAGCTGAAGCAATGCATTTATATAATATGTATACAAATATTGTTTT 2150
2161 GTAAATAAGTGTCTCGCTTTTTTATTTACTTTGGTATATTTTACACTAAGGACATTTCAA 2220
2221 ATTAAGTACTAAGGCAAAAGCATGTGTCATCCATCAGCAAAAGCACTACTTATATTTG 2250
2261 AGAGCAATTAAGCAGATTAAATAGTGGTCTTAAAGTCCATATGTTAAATGATTAGATGGT 2300
2341 TATATTACAATCATTTTATATTTTTTACATGATTACATTCACTTATGGATTGATGATG 2400
2401 GCTGTATAAAGTGAATTTGAAATTTCAATGGTTTACTGTGCTTGTGTTAAATCTCAAGC 2450
2461 TTCCATTATTTTAAATCTTGCAAAACATTACTAGTATAGCAAAATAATTCAGCTCTATT 2520
2521 ATCTGAAATGAGCAATAAAGTGTGCTATCTCAACATAACTGTTACTTTTATTTTATAA 2550
2581 TTTGATAATGAATATATTTCTGCATTTATTTACTTCTGTTTTGTAAATTCGGATTTTCTT 2600
2641 AATCAAAATTTATGTAATGACTAAATGAAATTTTCTTACATCTAATTTGTAGAAAC 2700
2701 AGTATAAGTTATATTAAAGTGTCTTTTCACTTTTTTGAAGAC 2743

```

FIG. 1d

5/28

FIGURE 2a

1/1
 ATG CAA AAA CTG CAA CTC TGT GTT TAT ATT TAC CTG TTT ATG CTG ATT GTT GGT GGT CCA
 M Q K L C L C V Y I Y L F M L I V A G P
 31/11
 61/21
 GTG GAT CTA AAT GAG AAC AGT GAG CAA AAA GAA AAT GTG GAA AAA GAG GGG CTG TGT AAT
 V D L N E N S E Q K E N V E K E G L C N
 91/31
 121/41
 GCA TGT ACT TGG AGA CAA AAC ACT AAA TGT TCA AGA ATA GAA CCC ATT AAA ATA CAA ATC
 A C T W R Q N T K S S R I E A I K I Q I
 151/51
 181/61
 CTC AGT AAA CTT CTT CTG GAA ACA GGT CCT AAC ATC AGC AAA GAT GGT ATA ACA CAA CTT
 L S K L R L E T A F N I S K D A I R Q L
 211/71
 241/81
 TTA CCC AAA GGT CTT CCA CTC CGG GAA CTG ATT GAT CAG TAT GAT GTC CAG AGC GAT GAC
 L P K A P P L R E L I D Q Y D V Q R D D
 271/91
 301/101
 AGC AGC GAT GGC TGT TTG GAA GAT GAC GAT TAT CAC GGT ACA ACG GAA ACA ATC ATT ACC
 S S D G S L E D D D Y H A T T E T I I T
 331/111
 361/121
 ATG CTT ACA GAG TGT GAT TTT TTA ATG CAA GTG GAT GGA AAA CCC AAA TGT TGC TTC TTT
 M P T E S D F L M Q V D G K P K C C F F
 391/131
 421/141
 AAA TTT AGC TGT AAA ATA CAA TAC AAT AAA GTG GTA AAG GGC CAA CTA TGG ATA TAT TTG
 R F S S K I Q Y N K V V R A Q L W I Y L
 451/151
 481/161
 AGA CTT GTC GAG AAT CTT ACA ACA GTG TTT GTG CAA ATT CTG AGA CTT ATC AAA CTT ATC
 R P V E C F T T V F V C I L R L I K P M
 511/171
 541/181
 AAA GAC GGT ACA AGC TAT ACT GGA ATC CGA TGT CTG AAA CTT GAC ATG AAG CCA GGC AGT
 K D G T R Y T G I R S L K L D M N P G T
 571/191
 601/201
 GGT ATT TGG CAG AGC ATT GAT GTG AAG ACA GTG TTG CAA AAT TGG CTG AAA CAA CTT GAA
 G I W Q S I D V K T V L Q N W L K Q P E
 631/211
 661/221
 TGC AAG TTA GGC ATT GAA AAT AAA GGT TTA GAT CAG AAT GGT CAT GAT CTT GGT GTA ACC
 S N L G I E I K A L D E N G H D L A V T
 691/231
 721/241
 TTC CCA GCA CCA GCA GAA GAT GGG CTG AAT CCC TTT TTA GAG GTC AAG GTA ACA GAC ACA
 F P G P G E D G L N P F L E V K V T D T
 751/251
 781/261
 CCA AAA AGA TGC AGA AGC GAT TTT GGT CTT GAC TGT GAT CAG CAC TCA ACA GAA TCG CGA
 P K R S R R D F G L D C D E H S T E S R
 811/271
 841/281
 TGC TGT COT TAC COT CTA ACT CTG GAT TTT GAA GGT CTT GCA TCG GAT TGG ATT ATC GGT
 C C R Y P L T V D F E A L G W D W I I A
 871/291
 901/301
 CTT AAA AGA TAT AAG GGC AAT TAC TGC TGT CGA GAG TGT GAA TTT GTA TTT TTA CAA AAA
 P K R Y K A N Y C S G E C E F V F L Q K
 931/311
 961/321
 TAT CTT CAT ACT CAT CTG GTA CAC CAA GCA AAC CCC AGA COT TCA CCA GGC CTT TGC TGT
 Y P H T H L V H Q A N P R G S A G P C C
 991/331
 1021/341
 ACT CCC ACA AAG ATG TGT CCA ATT AAT ATG CTA TAT TTT AAT GGC AAA GAA CAA ATA ATA
 T P T K M S P I N H L Y F N G K E Q I I
 1051/351
 1081/361
 TAT GCG AAA ATT CCA GCG ATG GTA GTA GAC GCG TCG GCG TCG TCA TCA
 Y G K I P A M V V D R C C C S -
 1111/371

6/28

FIGURE 2b

```

1/1
ATG CAA AAA CTG CAA ATC TCT GTT TAT ATT TAC CTA TTT ATG CTG ATT GTT GGT GGC CCA
M Q K L C I S V Y I Y L F M L I V A G P
61/21
CTG GAT CTG AAT GAG AAC AGC GAG CAG AAG GAA AAT CTG CAA AAA GAG GGC CTG TGT AAT
V D L N E N S E Q K E N V E K E G L C N
121/41
GCA TGT TTT TGG AGG GAA AAC ACT ACA TCC TCA AGA CTA GAA GCC ATA AAA ATC CAA ATC
A C L W R E N T T S S R L E A I K I Q I
131/61
CTC AGT AAA CTT CCC CTG GAA ACA GGT CTT AAC ATC AGC AAA GAT GGT ATC AGA CAA CTT
L S K L R L E T A P N I S K D A I R Q L
241/81
TTG CCC AAG GGT CTT CCA CTC CTG GAA CTG ATT GAT CAG TTC GAT GTC CAG AGA GAT GCC
L P K A P P L L E L I D Q F D V Q R D A
301/101
AGC AGT GAC GGC TCC TTG GAA GAC GAT GAC TAC CAC GGC AGC ACG GAA ACG GTC ATT ACC
S S D G S L E D D D Y H A R T E T V I T
361/121
ATG CCC AGC GAG TGT GAT CTT CTA ACG CAA GTG GAA GGA AAA CCC AAA TGT TCC TTC TTT
M P T E S D L L T Q V E G K P K C C F F
421/141
AAA TTT AGC TGT AAG ATA CAA TAC AAT AAA CTA GTA AAG GGC CAA CTG TGG ATA TAT CTG
K F S S R I Q Y N K L V K A Q L W I Y L
481/161
ATG CTT CTG AAG AAT CTT GCG ACA GTG TTT GTG CAA ATC CTG ACA CTG ATC AAA CCC ATG
R P V H T P A T V F V Q I L R L I K F M
541/181
AAA GAC GGT ABA AGG TAT ACT GGA ATC CGA TCT CTG AAA CTT GAC ATG AAC CCA GGC ACT
K D G T R Y T G I R S L K L D M N P G T
601/201
GGT ATT TCG CAG AGC ATT GAT GTG AAG ACA GTG TTG CAG AAC TCG CTC AAA CAA GGT GAA
G I W Q S I D V K T V L Q N W L K Q F E
661/221
TTC AAC TTA GGC ATT GAA ATC AAA GGT TTA GAT GAG AAT GGC CAT GAT CTT GGT GTA ACC
S N L G I E I K A L D E N G H D L A V T
721/241
TTG CTA GAA CCA GGA GAA GAT GGA CTG AAT CTT TTT TTA GAA CTG AAG GTA ACA GAC ACA
F P E F G E D G L T P F L E V K V T D T
781/261
CCA AAA AGA TGT AGG ACA GAT TTT GCG CTT GAT TGT GAT GAA CAC TCC ACA GAA TGT CGA
P K R S R R D F G L D C D E H S T E S R
841/281
TGC TGT COT TAC COT CTA ACT GTG CAT TTT GAA GGT TTT GGA TCG GAT TCG ATT ATT CCA
C C R Y P L T V D F E A F G W D W I I A
901/301
CCT AAA AGA TAT AAG GCC AAT TAC TCC TCT GGA GAA TGT GAA TTT GTA TTT TTG CAA AAG
P K R Y K A N Y C S G E C E F V F L Q K
961/321
TAT CTT CAT ACC CAT CTT GTG CAC CAA GCA AAC CCC AGA GGT TCA GGC GGC CCC TCG TGT
Y P H T H L V H Q A N P R G S A G P C C
1021/341
ACT CTT ACA AAG ATG TCT CCA ATT AAT ATG CTA TAT TTT AAT GGC GAA GGA CAA ATA ATA
T P T K M S P I N M L Y F N G E C Q I I
1081/361
TAC GCG AAG ATT CCA GGC ATG GTA GTA CAT CCG TGT GCG TGT TCA TCA
Y G K I P A M V V D R C G C S

```

Bovine GDF-8

7/28

FIGURE 2c

```

1/1                               31/11
ATG CAA AAG CTA GCA CTC TAT GTT TAT ATT TAC CTG TTC ATG CAG ATC GCG GTT GAT CCG
M Q K L A V Y V Y I Y L F M Q I A V D P
61/21                               91/31
GTG GGT CTG GAT GCG AGT AGT CAG CCC ACA GAG AAC GGT GAA AAA GAC GGA CTG TCG AAT
V A L D G S S Q P T E N A E K D G L C N
121/41                               151/51
GCT TGT ACC TCG AGA CAG AAT ACA AAA TCC TCC AGA ATA GAA GCG ATA AAA ATT GAA ATC
A C T W R Q N T K S S R I E A I K I Q I
131/61                               211/71
CTC AGC AAA CTG CCG CTG GAA CAA GCA CCT AAC ATT AGC AGC GAC GTT ATT AAG CAG GTT
L S K L R L E Q A P N I S R D V I K Q L
241/81                               271/91
TTA CCG AAA GGT CCT CCA CTG CAG GAA CTG ATT GAT CAG TAT GAT CTC CAG AGC GAC GAC
L P K A P P L Q E L I D Q Y D V Q R D D
301/101                               331/111
AGT AGC GAT GCG TGT TTG GAA GAC GAT GAC TAT CAT GCG ACA ACC GAG ACC ATT ATC ACA
S S D G S L E D D D Y H A T T E T I I T
361/121                               391/131
ATG CCT ACC GAG TGT GAT TTT CTT GTA CAA ATG GAG GGA AAA CCA AAA TGT TCG TTC TTT
M P T E S D F L V Q M E G K P K C C F F
421/141                               451/151
AAG TTT AGC TGT AAA ATA CAA TAT AAC AAA GTA GTA AAG GCA CAA TTA TGG ATA TAC TTG
K F S S K I Q Y N K V V K A Q L W I Y L
481/161                               511/171
AGC GAA CTC GAA AAA GTT ATA AGC GTG TTT GTG CAG ATC CTG AGA CTC ATT AAG CCG ATC
R C V C E P T T V F V C I L R L E R P M
541/181                               571/191
AAA GAC GGT ACA AGA TAT ACT GGA ATT CGA TTT TTG AAA CTT GAC ATG AAC CCA GCG ACT
R D G T R Y T G I R S L K L D M N P G T
601/201                               631/211
GGT ATC TCG CAG AGT ATT GAT GTG AAG ACA GTG CTG CAA AAT TCG CTC AAA CAG CCT GAA
G I W Q S I D V K T V L Q N W L K Q P E
661/221                               691/231
TCC AAT TTA GCG ATC GAA ATA AAA GGT TTT GAT GAG ACT GGA CGA GAT CTT CCT GTC ACA
S N L G I E I K A F D E T G R D L A V T
721/241                               751/251
TTC CCA GGA CCG GGT GAA GAT GGA TTG AAC CCA TTT TTA GAG CTC AGA GTT ACA GAC ACA
F P G P G E D G L N P F L E V R V T D T
781/261                               811/271
CTG AAA CCG TCC CCG AGA GAT TTT GCG CTT GAC TGT GAT GAG CAC TCA ACC GAA TCC CGA
P K R S R R D F G L D C D E H S T E S R
841/281                               871/291
TGT TGT CCG TAC CCG CTG ACA GTG GAT TTC GAA GGT TTT GGA TCG GAC TCG ATT ATA GCA
C C R Y P L T V D F E A F G W D W I I A
901/301                               931/311
CCT AAA AGA TAC AAA GCG AAT TAC TCG TCC GGA GAA TCG GAA TTT CTG TTT CTA CAG AAA
P K R Y K A N Y C S G E C E F V F L Q K
961/321                               991/331
TAC CCG CAC AGT CAC CTG GTA CAC CAA GCA AAT CCC AGA GCG TCA GCA GCG CCT TCG TCG
Y P H T H L V H Q A N P R G S A G P C C
1021/341                               1051/351
ACA CCG ACC AAG ATC TCC CCT ATA AAC ATG CTG TAT TTC AAT GGA AAA GAA CAA ATA ATA
T P T K M S P I N H L Y F N G K E Q I I
1081/361                               1111/371
TAT GGA AAG ATA CCA CCG ATG GTT GTA GAT CGT TCG GCG TCG TCA TCA
Y G K I P A M V V D R C C C S

```

8/28

FIGURE 2d

```

1/1                               31/11
ATG ATT CAA AAA CCG CAA ATG TAT GTT TAT ATT TAC CTC TTT GTC CTC ATT GGT GGT GGC
M I Q K F Q M Y V Y I Y L F V L I A A C
61/21                               91/31
CCA CTC GAT CTA AAT CAG GAC AGT CAG ACA CAG GCG AAT CTC CAA AAA CAG GCG CTC TGT
P V D L N E D S E R E A N V E K E G L C
131/41                               151/51
AAT GCG TGT CCG TCG ACA CAA AAC ACA AGC TAC TCC ACA ATA CAA GCG ATA AAA ATT CAA
N A C A W R Q N T R Y S R I E A I K I Q
131/51                               211/71
ATC CTC AGT AAA CTC CCG CTC GAA ACA GCG CTT AAC ATC AGC AAA GAT GGT ATA ACA CAA
I L S R L R L E T A P N I S K D A I R Q
241/51                               271/91
CTT CTC CCG ACA GCG CTT CCA CTC CCG GAA CTC ATC GAT CAG TAC GAC GTC CAG AGC GAT
L L P R A P P L R E L I D Q Y D V Q R D
301/101                               331/111
GAC AGC AGT GAC GCG TGT TTG GAA GAT CAC GAT TAT CAC GGT ACC AGC GAA ACA ATC ATT
D S S D G S L E D D D Y H A T T E T I I
351/121                               391/131
ACC ATG CTT ACC GAG TGT GAC TTT CTA ATG CAA GCG GAT GGA AAG CCG AAA TGT TCG TTT
T M P T E S D F L M Q A D G K P K C C F
421/141                               451/151
TTT AAA TTT ACC TGT AAA ATA CAG TAC AAC AAA GTC GTA AAG GCG CAG CTC TCG ATA TAT
F K P S S K I Q Y N K V V K A Q L W I Y
431/151                               511/171
CTC ACA GCG CTC AAG ACT CTT ACA ACA CTC TTT GTC CAA ATC CTC ACA CTC ATC AAA CCG
L R A V E T P T T V F V Q I L R L I R P
541/181                               571/191
ATG AAA GAC GGT ACA AGC TAT ACC GCA ATC CCA TGT CTC AAA CTT GAC ATG AGC CCA GCG
M K D G T R Y T G I R S L K L D M S P G
601/201                               631/211
ACT GGT ATT TCG CAG AGT ATT GAT CTC AAG ACA CTC TTG CAA AAT TCG CTC AAA CAG CTT
T G I W Q S I D V K T V L Q N W L K Q P
651/231                               691/231
GAA TCG AAG TTA CCG ATT GAA ATC AAA GGT TTG GAT CAG AAT GCG CAT CAT CTT GGT GTA
E S N L G I E I K A L E E N G H D L A V
721/241                               751/251
ACC TTC CCA GGA CCA GCA GAA GAT GCG CTC AAT CCG TTT TTA CAA CTC AAA GTA ACA GAC
T F P G F G E D G L N P F L E V K V T D
781/261                               811/271
ACA CCG AAG AGC TCG CCG ACA GAC TTT GCG CTT GAC TGT GAT GAA CAC TCG ACC GAA TCG
T P K R S R R D F G L D C D E H S T E S
841/281                               871/291
CGC TCG TGT CCG TAC CCG CTC ACG GTC GAT TTC GAA GCG TTT GCA TCG CAG TCG ATT ATT
R C C R Y P L T V D F E A F G W D W I I
901/301                               931/311
GCA CCG AAA ACA TAT AAG GGT AAT TAC TCG TGT GCA CAG TGT CAA TTT GTC TTC TTA CAA
A P K R Y K A N Y C S G E C E F V F L Q
961/331                               991/331
AAA TAT CCG CAT ACT CAT CTT GTC CAC CAA CCA AAC CCG ACA GCG TCG GCA GCG CTT TCG
K Y P H T M L V H Q A N P R G S A G P C
1021/341                               1051/351
TGG AGC CCA ACA AAA ATG TGT CCG ATT AAT ATG GTA TAT TTT AAT GCG AAA CAA CAA ATA
C T P T K M S P I N M L Y F N G K E Q I
1081/361                               1111/371
ATA TAT CCG AAA ATT CCA GCG ATC GTA GTA CAC CCG TGT CCG TCG TCG TCA
I Y G K I P A M V V D R C G C S

```

9/28

FIGURE 8e

1/1 31/11
 ATG CAA AAG CTA CCA CTC TAT GTC TAT ATT TAC CTC TTC ATG CAG ATT TTA GTT CAT CCG
 M Q K L A V Y V Y I Y L F M Q I L V H P
 61/21 91/31
 CTG CCG CTT CAT CCG AGT AGT CAG CCC ACA GAG AAC GGT CAA AAA CAG CCA CTC TCC AAT
 V A L D G S S Q P T E N A E K D G L C N
 121/41 151/51
 GGT TCC ACC TCC ACA CAG AAT AGT AAA TCC TCC ACA ATA CAA CCG ATA AAA ATT CAA ATC
 A C T W R Q N T K S S R I E A I K I Q I
 181/51 211/71
 CTC ACC AAA CTC CCG CTC CAA CAA CCA CTT AAC ATT AGC AGC CAG GTC ATT AAA CAA CTT
 L S K C R L E Q A P N I S R D V I K Q L
 241/81 271/91
 TTA CCG AAA CCG CCG CCG CTC CAG CAA CTC ATT CAT CAG TAT CAG CTC CAG AGA CAG GAG
 L P K A F P L Q E L I D Q Y D V Q R D D
 301/101 331/111
 AGT AGC CAT CCG TCC CTC GAA GAG GAT GAG TAT CAT CCG ACA ACC CAA ACC ATT ATC ACA
 S S D G S L Z D D D Y H A T T E T I I T
 361/121 391/131
 ATG CCG ACC CAG CCG CAT TTT CTC GTA CAA ATG GAG CCA AAA CCA AAA TGT TCG CTC TTT
 M P T E S D F L V Q M E G K P K C C F F
 421/141 451/151
 AAC TTT ACC TTT AAA ATA CAA TAT AAC AAA CTA CTA AAG CCA CAA TTA TCG ATA TAC CTC
 K F S S K I Q Y N X V V K A Q L W I Y L
 481/161 511/171
 ACC CAA CTC CAA AAA CTT ACA ACC GTC TTT CTC CAG ATC CTC ACA CTC ATT AAA CCG ATC
 R Q V Q R P T T V F V Q I L R L I K F M
 541/181 571/191
 AAA CAG CCG ACA AAA TAT AGT CCA ATT CCA TTT TTT AAA CTT CAG ATC AAC CCA CCG ATT
 K D G T R Y T G I R S L K L D M N P G T
 601/201 631/211
 CCG ATC TCG CAG AGT ATT CAT CTC AAC ACA GTC TCG CAA AAT TCG CTC AAA CAG CCG GAA
 G I W Q S I D V K T V L Q N W L R Q P Z
 661/221 691/231
 TCG AAT TTA CCG ACC CAA ACA AAA CCG TTT CAT CAG AAT CCA CCA CAT CTC CTT GTA ACA
 S N L G I E E K A F D E N G R E L A V T
 721/241 751/251
 TCG CCA CCA CCA CCG GAA GAT CCA CTC AAC CCA TTT TTA CAG CTC ACA GTT ACA CAG ACA
 F P G P G E D C L N F F L E V R V T D T
 781/261 811/271
 CCA AAA CCG TCG CCG ACA GAT TTT CCG CTT CAG TCG CAG CAG CAC TCA ACC GAA TGT CCA
 P K R S R A D F G L D C D E H S T E S R
 841/281 871/291
 TGT TGT CCG TAC CCG CTC ACA GTC GAT TTT CAA CCG TTT CCA TCG CAG TCG ATT ATA CCA
 C C R Y F L T V D F E A P G W D W I I A
 901/301 931/311
 CCG AAA ACA TAC AAA CCG AAT TAC TCG TCG CCA CAA TGT CAA TTC GTA TTT CTA CAG AAA
 P K R Y K A N Y C S G E C E F V F L Q K
 961/321 991/331
 TAC CCG CAG AGT CAG CTC GTA CAG CAA CCA AAT CCA AGA GCG TCA CCA CCG CCG TCG TCG
 Y P H T H L V H Q A N P R C S A G P C C
 1021/341 1051/351
 ACA CCG ACC AAG ATG TCG CCG ATA AAC ATG CTC TAT TTC AAT CCA AAA CCA CAA ATA ATA
 T P T K M S P I N H L Y F N C K E Q I I
 1081/361 1111/371
 TAT CCA AAG ATA CCA CCG ATG CCG GTA CAT CCG TCG CCG TCG TCA TCA
 Y G K I P A H V V D R C C C S

Turkey GDF-6

10/28


HEART
LUNG
THYMUS
BRAIN
KIDNEY
SEMINAL VESICLE
PANCREAS
INTESTINE
SPLEEN
TESTIS
FAT
UTERUS
OVARY
LIVER
MUSCLE

— 2.9 kb

FIG. 3a

GDF-8

11/28



GDF-8

Figure 3b

12/28

```

1  CCCCCCGACTCCCCCCCCCCCCCCCCCCCCAGTCTCTCCCTCCCCCTCCAGCATGCTCC  50
    M V L
61  TCCCCCCCCCCCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  100
    A A P L L L G F L L L A L E L R P R G E
121  ACCCCCCCCCCAGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC  150
    A A E G P A A A A A A A A A A A A A A A A G V
181  TCCCCGGGGAGCCCTCCAGCCCCCCCCCCCCCTCCCTCTCTCTCTCTCTCTCTCTCTCT  200
    G G E R S S R P A P S V A P E P D G C F
241  CCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  250
    V C V W R Q H S R E L R L E S I K S Q I
301  TCTTGAAGCACTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  350
    L S K L R L E E A P N I S R E V V H Q L
361  TCTCTCCCCAAGCCCCCCCCCCCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  400
    L P K A P P L Q Q I L D L E D F Q G D A
421  CCTCTCAGCCCCCAGGAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  450
    L Q P E D F L E E D E V H A T T E T V I
481  TTACCATCCCCCAGGAGAGCCGAGCCGAGCACTCTCTCTCTCTCTCTCTCTCTCTCTCT  500
    S M A Q E T D P A V Q T D G S P L C C H
541  ATTCTCACTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  550
    F H F S P K V M F T K V L K A Q L W V Y
601  ACTTACGGCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  600
    L R P V P R P A T V Y L Q I L R L K P L
661  TACTGGGGAAAGGAGAGCCGAGCCGAGCCGAGCCGAGCCGAGCCGAGCCGAGCCGAGCC  700
    T G E G T A G G G G G G G R R H I R I R S
721  CATCTAAGATTCAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  750
    L K I E L H S R S G H W Q S I D F K Q V
781  TCTTACAGAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  800
    L E S W F R Q P Q S H W G I E I N A F D
841  ATCCCACTGGCCAGAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  850
    P S G T D L A V T S L G P G A E G L H P
901  CATCTATGGAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  900
    F M E L R V L E N T K ELMSIPRAMEL N L G L D
961  ACTCCGAGCAGCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1000
    C D E E S S E S R C C R Y F L T V D F E
1021  AGCTTTCTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1050
    A F G W D W I I A P K R Y K A N Y C S G
1081  GCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1100
    Q C E Y M F M Q K Y P H T H L V Q Q A N
1141  ATCCAGAGAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1150
    F R G S A G P C C T P T K M S P I N M L
1201  TCTACTTCATTCAGAGCCAGCATTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1200
    Y F N D K Q Q I I Y G K I P G M V V D R
1261  CCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1250
    C G C S *
1321  TACTTAACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT  1300
    AGCTTAAAGGCT 1393

```

FIGURE 4A

GDF-11

13/28




FIGURE 4B

GDF-11


14/28

1

CHO HGDF-8


Figure 5

90%
pure.




15/28

Figure 6
GDF-8 Binding to L6 Myoblast Cells



GDF-8 Binding to G8 Myoblast Cells

Figure 7



17/28

Figure 8
GDF-8 Binding to C2C12 Myoblast Cells






Figure 9
GDF-8 Binding to G7 Myoblast Cells




19/28

Figure 10
GDF-8 Binding to ALB13MYC c14 Cells



20/28

Figure 11
GDF-8 binding to BC3H1 Cells



21/28




Fig. 12A

22/28




Fig. 12B

23/28

# of normal size kidneys	2	1	1	0	0	0
# of small kidneys	0	1	0	2	1	0

+/+	47	0	0	0	0	0
+/-	88	0	5	0	0	0
-/-	2	2	9	3	3	28

Fig. 13

24/28




Fig. 14A

25/28

Fig. 14B - 14D




Fig. 14E - 14G





Fig. 14H - 14J



28/28

Fig. 15 Anterior transformations in wild-type, heterozygous and homozygous GDF-11 mice

	Wild-type		Heterozygous		Homozygous	
	Hybrid	129/SvJ	Hybrid	129/SvJ	Hybrid	129/SvJ
Presacral vertebrae ^a						
25	4	1	-	-	-	-
26	18	6	1	-	-	-
27	-	-	58	6	-	-
33	-	-	-	-	18	2
34	-	-	-	-	5	-
Vertebral pattern ^{a,b}						
C7 T13 L5	4	1	-	-	-	-
C7 T13 L6	18	6	-	-	-	-
C7 T13 L7 ^c	-	1	-	-	-	-
C7 T14 L5	-	-	1	-	-	-
C7 T14 L6	-	-	58	6	-	-
C7 T17 L9	-	-	-	-	1	1
C7 T18 L8	-	-	-	-	17	1
C7 T18 L9	-	-	-	-	5	-
C7 T18 L7 ^c	-	-	-	-	-	1
Anterior tuberculus on						
No vertebrae	-	1	-	-	-	-
C6	22	7	59	5	21	1
C6 and C7 ^d	-	-	-	1	2	2
Attached/unattached ribs ^b						
7/6	22	8	-	-	-	-
8/6	-	-	59	6	-	-
10/7	-	-	-	-	-	1
10/8 ^e	-	-	-	-	13	2
11/6	-	-	-	-	1	-
11/7	-	-	-	-	4	-
10 + 11/8 + 7 ^f	-	-	-	-	5	-
Longest spinous process on						
T2	22	5	41	-	2	-
T3	-	-	6	6	16	-
T2 + T3 equal	-	1	8	-	1	-
T3 + T4 equal	-	-	-	-	-	2
Transitional spinous process on						
T10	22	8	3	-	-	-
T11	-	-	56	6	-	-
T12	-	-	-	-	1	-
T13	-	-	-	-	22	3
Transitional articular process on ^g						
T10	22	8	1	-	-	-
T11	-	-	58	6	-	-
T13	-	-	-	-	23	3

^aVertebrae that were lumbar on one side and sacral on the other were scored as sacral. These vertebrae were seen in 2 wild-type, 3 heterozygous and 8 homozygous mutants in the hybrid background.

^bOne hybrid heterozygous, 9 hybrid homozygous and 2 129/SvJ homozygous mutants had rudimentary ribs on the most caudal thoracic segment.

^cThe number of lumbar vertebrae could not be counted due to extensive fusion of lumbar segments.

^dThese animals had a unilateral transformation of the anterior tuberculi. One 129/SvJ homozygous mutant retained one tuberculus on C6 but had bilateral tuberculi on C7.

^eOne 129/SvJ homozygous mutant had the first rib attached to the second rather than the sternum on one side only. Ten ribs were attached to the sternum on the other side.

^fRibs were asymmetrically attached.

^gOne wild-type 129/SvJ had one transitional articular process on T10 and one on T11 (scored as T10). One hybrid heterozygous mutant mice had one process on T11 and one on T12 (scored as T11).

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/15598

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 15/12; G01N 33/53

US CL :435/325, 7.21; 530/412

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/325, 7.21; 530/412

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases: Medline, Biosis, Embase, SciSearch, EPO online, Derwent WPI

Keywords: GDF, growth differentiation factor, receptor

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HANNON, K. et al. Differentially expressed fibroblast growth factors regulate skeletal muscle development through autocrine and paracrine mechanisms. Journal of Cellular Biochemistry. March 1996, Vol. 132, No. 6, pages 1151-1159, especially the abstract.	1, 2
Y — A	MCPHERRON, A.C., et al. Regulation of skeletal muscle mass in mice by a new TGF-Beth superfamily member. Nature. 01 May 1997, Vol. 387, No. 6628, pages 83-90, especially the abstract.	23, 24 ----- 1, 22
Y - A	US 5,639,638 A (WOZNEY et al) 17 June 1997, columns 1, 6.	23, 24 ----- 1, 22

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 SEPTEMBER 1998

Date of mailing of the international search report

19 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID L. FITZGERALD

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/15598

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 3-22 and 25-41
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)